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Abstract 
 Alzheimer disease is a progressively devastating neurodegenerative disease of the brain 
that impairs cognition and is ultimately fatal. Cholinesterase inhibitors are the current 
standard treatment for Alzheimer disease and they can alleviate some of the symptoms and 
thus improve quality of life. Cognitive measures aid in the diagnosis and monitoring of 
individuals with Alzheimer disease, but they do not directly measure disease 
pathophysiology. The purpose of this thesis is to investigate metabolic changes measured 
with proton magnetic resonance spectroscopy within the hippocampus and posterior 
cingulate, two brain regions known to be effected in Alzheimer disease, following 
cholinesterase inhibitor treatment. Such treatment is aimed at increasing the deficit of 
acetylcholine in Alzheimer disease. Secondly, to develop a 7 Tesla proton magnetic 
resonance spectroscopy data acquisition and metabolite quantification protocol to be used for 
future studies. 
 In one study, proton magnetic resonance spectroscopy at 4 Tesla was used to measure 
the effects of four months of galantamine treatment (a cholinesterase inhibitor). An increase 
in the excitatory neurotransmitter glutamate was detected in the right hippocampus, and was 
associated with increased cognitive performance. In a second study, proton magnetic 
resonance spectroscopy at 3 Tesla was used to measure the effects of rivastigmine (a second 
cholinesterase inhibitor). The ratio of the neuronal marker N-acetylaspartate to creatine was 
decreased in the bilateral posterior cingulate cortex, which was associated with cognition. 
 iii 
 Finally, a quantitative proton magnetic resonance spectroscopy protocol at 7 Tesla was 
developed that incorporates subject-specific macromolecule removal. Absolute in vivo 
metabolite concentrations measured were in agreement with previous studies, and this 
protocol is ideal for applications in diseased conditions where macromolecule contributions 
may deviate from the norm. 
 
 
Keywords: Alzheimer disease, cholinesterase inhibitors, galantamine, glutamate, high 
magnetic field, macromolecule removal, Magnetic Resonance Spectroscopy, metabolite 
quantification, N-acetylaspartate, rivastigmine 
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Chapter 1 
 
Introduction 
 The goal of this thesis is to use proton magnetic resonance spectroscopy (1H MRS) to 
characterize metabolite changes in the brain following cholinesterase inhibitor (ChEI) 
treatment in people with Alzheimer disease (AD). Further, a short echo-time 1H MRS 
acquisition and metabolite quantification scheme is to be developed for use in humans at a 
magnetic field strength of 7 Tesla (T). This chapter introduces the neuropathology, diagnosis, 
and treatment of AD along with current imaging biomarkers under development to monitor 
disease status and progression. This chapter also describes the magnetic resonance (MR) 
theory and MRS methodology relevant to the proceeding chapters. 
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1.1  Alzheimer disease 
1.1.1 Overview 
 Alzheimer disease (AD) is a progressive and neurodegenerative disease of the brain 
and is the most common cause of dementia. AD is symptomatically characterized by 
progressive loss in memory, language, executive, and visuospatial function, an inability to 
perform acts of daily living, and altered personality or mood. It therefore has a profound 
impact on those diagnosed with the disease and their caregivers. There is currently no known 
cure for AD, with death occurring approximately seven to ten years after it is clinically 
evident (Alzheimer’s Society of Canada, January 2009). The Alzheimer’s Society of Canada 
estimates that half a million Canadians have AD, and 24 million worldwide (January 2009). 
With the aging global population and the fact that age is a risk factor for AD, this disease will 
become an even greater burden to our health care system in the coming decades. 
 
1.1.2 Neuropathology 
 The neuropathology of AD was first described in 1906 by German psychiatrist and 
neuropathologist Alois Alzheimer (1), after whom the disease was named. Alois Alzheimer 
first identified numerous senile plaques and densely twisted bundles of neurofibrils on post-
mortem histological tissue stains from an individual who suffered from a unique progressive 
dementia (2). These have more recently been identified as !-amyloid (A!) plaques and 
neurofibrillary tangles (NFTs) and are the key pathological hallmarks of AD. A! plaques and 
NFTs are abnormal accumulations of two separate misfolded proteins. A! plaques are found 
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outside of neurons (extracellular) (3) and consist of aggregated A! peptides of 40-42 amino 
acids (4). A! plaques are in close proximity to nerve cells and are neurotoxic. Neurofibrillary 
tangles form inside neurons (intracellular) and are an accumulation of hyperphosphorylated 
tau protein (5). Tau is a protein that aids in the maintenance of microtubules, which provide 
support to the neuron. 
 Other neuropathological effects of AD include increased microglial and astroglial cell 
activation and significant brain tissue atrophy. Further, in AD there is a reduction in 
acetylcholine (ACh), which is a neurotransmitter of the central nervous system (CNS). The 
pathological alterations observed in AD start in the paralimbic and medial temporal lobe 
(MTL) structures, including the hippocampus and entorhinal cortex, and later move into the 
neocortical association areas (6). Eventually, the gradual cortical atrophy caused by neuronal 
dysfunction and decreased synaptic connectivity results in cognitive and executive function 
deficits (7,8). 
 
1.1.3 Diagnosis and clinical assessments 
 The National Institute of Neurological and Communicative Disorders and Stroke and 
the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) formulated 
criteria for the definition of Alzheimer disease in 1984, and these are commonly used for the 
diagnosis of AD (9). These criteria lead to a diagnosis of probable AD based on cognitive 
impairment with suspected dementia backed up by neuropsychological evaluation. The 
impaired cognitive domains include: memory, language (aphasia), perceptual skills (agnosia), 
attention, constructive abilities, orientation, problem solving, and functional abilities (9). 
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Family history may also help in the diagnosis of AD. 
 Cognitive assessments, designed to evaluate cognitive performance, are predominantly 
used to diagnose and monitor the clinical progression of AD. The most common clinical 
cognitive test is the Mini-Mental State Examination (MMSE), which consists of eleven items 
designed to evaluate 5 domains: memory, orientation, attention, language, and motor skills 
(10). MMSE scores range from a value of 30, indicating no impairment, to a value of 0, 
indicating profound impairment. A second widely used clinical trials cognitive test and 
primary cognitive outcome measure, is the Alzheimer Disease Assessment Scale-cognitive 
subscale (ADAS-cog), which consists of seven performance items and four clinical rating 
items covering memory, orientation, and language (11). ADAS-cog score values range from 
0, no impairment, to a value of 70, severe impairment. The MMSE and ADAS-cog offer 
modest sensitivity to AD (11-13), but lack specificity (11-13). The Montreal Cognitive 
Assessment (MoCA) is another clinical cognitive test developed for use in people with mild 
cognitive impairment (MCI) and early AD (14). The MoCA is therefore more sensitive in 
early AD, but is not yet as commonly used in clinical evaluation despite numerous studies 
showing its high sensitivity in the detection of MCI and AD (15-23). The MoCA assesses 8 
domains: attention and concentration, executive functions, memory, language, 
visuoconstructional skills, conceptual thinking, calculations, and orientation, with a perfect 
score equal to 30. 
 Complicating the differential diagnosis of AD are other forms of dementia, including 
vascular dementia, dementia with Lewy bodies, and frontotemporal dementia, often 
presenting with overlapping symptoms. Furthermore, other causes of cognitive decline 
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include hematoma, normal pressure hydrocephalus, tumour, and stroke (24). As a result, 
Alzheimer disease clinical diagnostic criteria result in specificity between 76% and 88% and 
sensitivity between 53% and 65% (25), and therefore there is room for improvement. 
Currently a definitive diagnosis of AD can only be made upon post-mortem histopathological 
confirmation (6). The diagnostic accuracy of AD may be improved with the inclusion of 
cerebral spinal fluid (CSF) biomarkers and neuroimaging markers. 
 
1.1.4 Treatment 
 Significant research resources are being allocated to the development of disease 
modifying therapies that could slow or prevent further progression of Alzheimer disease (24), 
however no such therapies are currently available. The standard of care for patients with AD 
is treatment with a cholinesterase inhibitor (ChEI) (26,27). 
 Reduced levels of the neurotransmitter acetylcholine (ACh) in AD contributed to the 
formation of the cholinergic hypothesis (28), which proposes that AD involves reduced 
synthesis of acetylcholine and in turn leads to reduced cholinergic neurotransmission (29,30). 
Pharmaceuticals known as cholinesterase inhibitors (ChEI) have been developed to improve 
cholinergic neurotransmission by inhibiting the breakdown of ACh within the synaptic cleft 
by the enzyme acetylcholinesterase (AChE). Currently in clinical use are rivastigmine, 
donepezil, and galantamine, which are all second-generation ChEIs and have been proven to 
improve cognition with similar cognitive efficacy in a meta-analysis of all three drugs (31). 
However, cognitive improvements with ChEI treatment are only temporary because they do 
not modify the underlying disease process. 
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 Memantine is the only clinically approved drug for the treatment of AD that does not 
act on the cholinergic pathway, but rather it is a N-methyl-D-aspartate (NMDA) receptor 
antagonist. Over stimulation of NMDA receptors can lead to an excess of Ca2+ ions within 
the neuron, potentially leading to cell death; also known as excitotoxicity. Memantine 
inhibits excitation of NMDA receptors and therefore reduces excitotoxity. 
 
1.2  Neuroimaging of Alzheimer disease 
 The diagnosis of Alzheimer disease is currently based on clinical evaluations and 
patient histories and neuroimaging is used to rule out other diseases with similar cognitive 
deficits, such as hematoma, normal hydrocephalus, brain glioma, and stroke (24). Further, 
neuroimaging is a promising area of research because it can provide quantitative measures of 
the underlying disease pathology, beyond clinical cognitive endpoints. Alzheimer’s disease is 
being studied with many different neuroimaging techniques in an effort to find biomarkers of 
disease progression that are sensitive and specific early in the disease process. Such 
biomarkers will improve diagnosis and monitoring of disease status. Early diagnosis will 
become vital when disease-modifying therapies are available, allowing for intervention 
before the pathological processes of amyloid protein plaque formation and tau protein 
neurofibrillary tangle creation is too advanced (6,32). 
 
 
 
 
! 7 
1.2.1 Magnetic Resonance Imaging  
 Magnetic resonance imaging (MRI) uses only non-ionizing radiation and is capable of 
producing high-resolution structural images (~1 mm3 voxel size) with excellent soft tissue 
contrast. This capability is due in part to the high water content of soft tissue (~56 mol/L), as 
water molecules contain protons that are used to generate the in vivo MRI signal. 
Longitudinal MRI studies have shown structural changes in Alzheimer disease including 
decreased volume of the hippocampus (33-36), in one study distinguishing normal controls 
from AD with 93.3% specificity and 80.6% sensitivity (36). Studies have also shown 
increased volume of the fluid-filled spaces known as the ventricles (37), and global atrophy 
(38-40), where one study reported 91% specificity and 84% sensitivity in classifying control 
versus AD (40). However, these structural changes may also occur in other forms of 
dementia and therefore their specificity is unclear. As a result, they are often used in 
combination with cognitive measures. 
 
1.2.2 Positron Emission Tomography 
 Positron Emission Tomography (PET) is an imaging modality that detects and creates 
images from nuclides that emit positrons, which in turn release two gamma rays in opposite 
direction. The two gamma rays interact with the PET detectors at two different locations and 
this information is used to determine where they originated. Positron-emitting nuclides can 
be attached to naturally occurring molecules and are known as radiotracers, which can then 
be injected intravenously to create images of targeted biological processes. 
 In Alzheimer disease there are two radiotracers that have been most widely studied. 
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First is fluorodeoxyglucose (FDG), which consists of a positron emitting 18F-labeled 
deoxyglucose. FDG travels throughout the body and is found in higher concentrations in 
regions with heightened glucose energy metabolism. FDG-PET is therefore used to image 
glucose metabolism and has shown widespread decreased metabolism in the brains of AD 
patients, especially in the posterior cingulate, temporoparietal cortex, and prefrontal cortex 
(41-43). A previous study reported 51.5% specificity at 80% sensitivity in discriminating 
health controls from those that converted to MCI or AD based on medial temporal and 
parietal FDG-PET (44). Second, is Pittsburg compound B ([N-Methyl-11C]2-(4'-
methylaminophenyl)-6-hydroxybenzothiazole), which is labeled with a positron emitting 11C. 
PiB binds to !-amyloid plaques and studies have shown heightened cortical PiB retention in 
the brains of AD patients (45-48), and a previous study reported 94.4% specificity and 94.4% 
sensitivity in discriminating controls from AD based on PiB binding in the precuneus (48). 
More recently, multiple 18F amyloid binding agents (florbetapir, florbetaben, NAV4694) 
have shown promise in detecting fibrillary amyloid. The major advantage of 18F compounds 
over PiB is due to the longer radioactive half-life of 18F (110 mins) compared to 11C (20 
mins), negating the need for an on-site cyclotron and radiochemistry expertise (49). A 
limitation of PET is that radiotracers contain radioactive isotopes and therefore they deposit 
ionizing radiation into the body. For example, a typical brain FDG scan results in an effective 
radiation dose of 14 mSv (50), compare that to 2 mSv for a typical head CT scan (50) and the 
average annual dose from background radiation of 3 mSv/year in the United States (50). 
However, a PET scan may aid in diagnosis and therefore the benefits may outweigh the 
radiation risk. 
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1.2.3 Magnetic Resonance Spectroscopy 
 Metabolic alterations induced by Alzheimer disease pathological processes are thought 
to precede detectable structural and cognitive changes, and therefore metabolite levels may 
provide early biomarkers. Proton (1H) MRS is a non-invasive imaging technique capable of 
directly detecting mobile metabolites in the human brain with concentrations greater than 
approximately 0.5 mmol/L (mM) (51). Typical in vivo brain metabolite concentrations range 
from 1 to 15 mM. The most abundant metabolites, and therefore most easily measured by 1H 
MRS, in the human brain are N-acetylaspartate, glutamate, creatine-containing compounds, 
choline-containing compounds, and myo-inositol. 
 
1.2.3.1 N-acetylaspartate 
 N-acetylaspartate (NAA) is an amino acid found primarily within neurons in the human 
brain, and the concentration of NAA within neurons is roughly one thousand times the 
concentration in the extracellular space (52). More specifically, 75% of the NAA content 
within a neuron is found in the cytosol and 25% in the mitochondria (52). The fact that 
essentially all of the NAA is within neurons has lead to an interest in relating NAA levels to 
changes in neurological diseases. NAA levels are often equated to neuronal density or 
viability. Previous studies have reported decreased NAA in subjects with AD compared to 
elderly controls in the parietal and occipital cortex (53), gray matter (54,55), hippocampus 
(56-58), and posterior cingulate (59). Further, reversible changes in NAA levels have been 
reported following treatment in neurological disorders, suggesting that NAA is reduced 
before cell death occurs. This decline could be explained by reversible mitochondrial 
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dysfunction, as NAA synthesis has been linked to mitochondrial activity in vitro (60) and the 
pathogenesis of neurodegeneration often involves mitochondrial dysfunction (61). Therefore, 
NAA depletion may represent a combination of reduced neuronal density and impaired 
neuronal function. Therefore, NAA may be an indicator of therapeutic efficacy in AD. 
 The multifaceted role of NAA is not entirely understood but it has been shown that 
glucose metabolism is linked to the production of NAA (62), and therefore NAA synthesis is 
related to energy metabolism within neurons. This relationship is further supported by the 
fact that glucose is a source for acetate and aspartate, the constituents of NAA. Further, the 
hydrolysis of NAA into acetate and aspartate, and subsequent active transport out of the 
neuron, acts as a molecular water pump to maintain a higher extracellular concentration of 
water (63). 
 The concentration of NAA in the human brain is approximately 10 mM, which makes 
it one of the most abundant metabolites in human brain. NAA is easily identified in in vivo 
1H MRS spectra because of its larger single peak at 2.01 ppm. 
 
1.2.3.2 Glutamate 
 Glutamate (Glu) is the most abundant excitatory neurotransmitter of the central nervous 
system. Glu is stored in vesicles and is released from the pre-synaptic neuron during 
neurotransmission and can subsequently bind to post-synaptic N-methyl-D-aspartate 
(NMDA) receptors. When Glu binds to a NMDA receptor, ions such as Ca2+ flow into the 
postsynaptic neuron. Glu excitotoxicity is a feature of AD (64) and occurs when excess Glu 
accumulates in the synaptic cleft binding to NMDA receptors and causing an excess influx of 
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Ca2+, and the excessively high intracellular Ca2+ concentration leads to mitochondrial 
damage (64). In healthy brain tissue glutamate transporters primarily found on membranes of 
astrocytes (a type of glial cell) take up Glu, and within the astrocyte glutamine synthetase 
converts Glu into its precursor glutamine (Gln) (65). Gln is then transported across the 
extracellular space back into the presynaptic neuron where it is synthesized into Glu, thereby 
avoiding excess Glu accumulation in the extracellular space (65). Previous studies have 
reported decreased Glx (Glu + Gln) in subjects with AD compared to elderly controls in 
occipital gray matter (54), in the cingulate cortex (66), and in the posterior cingulate gyrus 
and precuneus (67). Thus, it is becoming increasingly important to understand how Glu could 
be used as a biomarker for AD. 
 The concentrations of Glu and Gln in the human brain are approximately 8-10 mM and 
2-3 mM, respectively. Glu and Gln produce J-coupled multiplets in the in vivo 1H MRS 
spectrum in the range of 2.0-2.5 ppm. Separating the overlapping peaks from Glu and Gln is 
challenging and sometimes infeasible, especially at magnetic fields strengths equal to or 
below 3 Tesla, and therefore the sum of Glu and Gln (Glx) is often reported in the literature. 
 
1.2.3.3 Creatine 
 The sum of creatine (Cr) and phosphocreatine (PCr) is referred to as total Cr (tCr) in 
this thesis, and Cr and PCr are in constant exchange (68). More specifically, PCr serves as a 
reserve for high energy phosphates in the cytosol and buffers cellular ATP/ADP reservoirs 
(69). PCr is therefore used as an energy marker of both neurons and astrocytes (68). 
 The total concentration of Cr plus PCr in the human brain is approximately 8-9 mM 
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and both Cr and PCr produce strong single peaks at ~3.0 and ~3.9 ppm, which are easily 
identified in in vivo 1H MRS spectra. Measurement of metabolite levels from MRS often uses 
tCr as a normalization reference. This approach is used because tCr levels have been shown 
to be fairly stable within an individual over time (54), and because taking the ratio of two 
metabolites eliminates the need for tissue partial volume corrections and results in a unit-less 
quantity that is easy to compare between scanners and research laboratories. 
 
1.2.3.4 Choline 
 Glycerolphosphocholine (GPC) and phosphocholine (PC), which are commonly 
summed and reported as Cho (GPC + PC) in the literature and in this thesis, are essential for 
membrane lipid synthesis (68). Increased Cho is thought to reflect higher membrane turnover 
resulting in the increased release of water soluble Cho containing compounds from the cell 
membrane (68). Increased Cho has been reported in AD in bilateral posterior cingulate gyri 
and inferior precunei (70), as compared to elderly controls. It has been theorized that an 
increase in Cho can also result from a compensatory reaction to low levels of acetylcholine 
due to cholinergic neuronal death in AD (71). 
 The total concentration of Cho (PC + GPC) in the human brain is approximately 1-2 
mM, which is lower than NAA, Glu, and tCr. However, Cho produces a strong single peak at 
~3.2 ppm and therefore is nonetheless easily identified in in vivo 1H MRS spectra. 
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1.2.3.5 myo-Inositol 
 Myo-inositol (mI) is a cyclic sugar alcohol produced by the human body from glucose, 
and plays an important role as the structural basis for a number of secondary messengers in 
eukaryotic cells (72). Myo-inositol is thought to be a marker of gliosis, which is the 
proliferation of glial cells, partly because glial cells are known to have a high concentration 
of mI (73). Gliosis is often associated with neuronal atrophy or inflammation of neural tissue. 
Increased mI has been reported in AD in parietal and occipital cortex (53), bilateral posterior 
cingulate gyri and inferior precunei (70), gray matter (54), and bilateral posterior cingulate 
(59). This increase in mI may be indicative of the aggregation of glial cells. Another theory is 
that the conversion of mI into phosphatidylinositol, used in neural membranes, is inhibited in 
AD, causing a build-up of mI and a depletion of phosphatidylinositol (74). 
 The concentration of mI in the human brain is approximately 5-6 mM, and mI produces 
a strong, easily identified multiplet centred at ~3.5 ppm in in vivo 1H MRS spectra. 
 
1.2.3.6 MRS metabolite measurement for treatment efficacy 
 1H MRS metabolite level measurement is an excellent potential biomarker of treatment 
efficacy due to a number of reasons. Firstly, 1H MRS is a non-invasive imaging method that 
yields in vivo metabolite concentrations and can easily be added to standard imaging 
protocols without affecting other imaging measures or cognitive testing. Secondly, 
metabolite levels are quantitative measures of chemical species, and therefore are not 
affected by subject performance, mood, or wakefulness. Further, metabolic alterations caused 
by Alzheimer disease are thought to precede detectable structural and cognitive changes, 
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potentially allowing for earlier detection and earlier response to treatment. More specifically 
with beneficial treatment: NAA can be used as a biomarker of neuronal density or function 
and should increase to normal levels, Glu can be used to measure excitatory 
neurotransmission that should increase to normal levels, Cho can be used to measure cellular 
turnover or regrowth and should decrease to normal levels, and mI can be used to measure 
atrophy or inflammation of neurons (associated with gliosis) and should decrease to normal 
levels. 
 
1.3  Principles of Magnetic Resonance 
 The studies detailed in this thesis utilize proton magnetic resonance (MR) imaging and 
MR spectroscopy to measure metabolites in the human brain, and therefore the basic theory 
of magnetic resonance will be provided in this section. Symbols with an arrow on top 
represent vector quantities that have a magnitude and a direction. 
 
1.3.1 Magnetization 
 Nuclear magnetic resonance can be described classically or quantum mechanically. The 
concept of quantum spin can only be described by quantum mechanics, but classical 
principles will be used to explain the behaviour of the macroscopic magnetization. 
 The phenomenon of nuclear magnetic resonance occurs when a nucleus with a 
magnetic moment (  
! 
! 
µ ) is placed in a magnetic field (  
! 
! 
B ). The magnetic field will exert a 
rotational force, or torque (  
! 
! 
" ), on the magnetic moment given by the following cross-
product: 
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!
! =
!
µ !
!
B = µBsin"            (1.1) 
  
where " is the angle between the two vectors. The direction of the torque is normal to the 
plane defined by   
! 
! 
µ  and   
! 
! 
B , leading to precession of the nucleus about   
! 
! 
B . Further, the torque 
is zero when   
! 
! 
µ  is either parallel or anti-parallel to   
! 
! 
B as sin(0°) = sin(180°) = 0, and therefore 
precession only occurs when   
! 
! 
µ  and   
! 
! 
B are not in the same direction. The angular frequency 
of the precession is known as the Larmor frequency (
! 
" 0) and is given by: 
 
! 
" 0 = #B0            (1.2) 
 
 A magnetic moment in a magnetic field has potential energy (E) defined by the 
following dot-product: 
 
E = ! !µ "
!
B = !µBcos!            (1.3) 
 
The convention in MRI is to set the z-direction along   
! 
! 
B , such that 
!
B = B0 zˆ . Since 
! 
B0  is only 
in the z-direction, the dot-product in Equation 1.2 yields: 
 
! 
E = "µzB0             (1.4) 
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where 
! 
µz  and 
! 
B0  are in the z-direction. 
 The magnitude of the spin angular momentum (  
! 
! 
S ) of a nucleus is given by: 
 
S = ! s(s+1)                 (1.5) 
 
where s  the associated quantum number with values equal to 0, 1/2, 1, 3/2, 2, …, and !  is 
Planck’s constant divided by 2#. Therefore, nuclei with a non-zero spin quantum number 
have a non-zero spin angular momentum and an associated magnetic moment: 
 
µ = !S                    (1.6) 
 
where 
! 
"  is the gyromagnetic ratio that is unique to each nucleus. Substituting Equation 1.4 
into Equation 1.5 gives: 
 
µ = !! s(s+1)          (1.7) 
 
therefore the magnetic momentum is quantized. The discrete set of possible 
! 
z  components of 
the magnetic moment is given by another quantum number, 
! 
m : 
 
µz = !!m            (1.8) 
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and there are 2 s  + 1 values of m given by - s , s  + 1, …, s  - 1, s. Substituting Equation 1.7 
into Equation 1.3 yields: 
 
E = !!!mB0                (1.9) 
 
 the 2 s  + 1 values for the potential energy of the magnetic moment in a magnetic field. 
 The probability (
! 
Pm ) that a nucleus is in the quantum energy state 
! 
m  is given by the 
Boltzmann distribution: 
 
! 
Pm =
Nm
N
=
e "E / kT
Z         (1.10) 
 
where 
! 
Nm  is the number of nuclei in state 
! 
m , N  is the total number of nuclei, k is the 
Boltzmann constant (1.3805 x 1023 Joules/Kelvin), T  is the temperature in Kelvin, and 
! 
Z  is 
the partition function for an ensemble of spins. The equilibrium longitudinal magnetization 
(
! 
M 0) can be derived (75) from the average 
! 
µz  over the total number of nuclei using Equation 
1.9 and the fact that kT >> !!B0  at physiological temperatures: 
 
M0 =
N! 2!2s(s+1)B0
3kT             (1.11) 
 
This net macroscopic magnetization of an ensemble of spins is aligned with the static 
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magnetic field at thermal equilibrium. There are two reasons for this alignment: (i) magnetic 
moments aligned with B0 are in the lower energy state according to Equation 1.8 and (ii) 
there is no net transverse magnetization as the spins are randomly distributed (incoherent) in 
the transverse plane. However, the thermal energy of the system acts to equalize the number 
of magnetic moments in each energy state, resulting in only a small excess of spins in the 
lower energy state (on the order of one in a million). 
 Magnetic resonance scanners are designed to detect magnetization that is perpendicular 
to the B0 direction (in the transverse plane), and therefore the equilibrium magnetization in 
the z-direction must be manipulated to produce transverse magnetization that can be 
detected. 
  
1.3.2 Excitation 
 Excitation refers to the process of generating detectable transverse magnetization 
( Mxy = Mx2 +My2 ) from the longitudinal magnetization, 
!
M , and is accomplished by 
applying a transverse magnetic field (
!
B1 ). The 
!
B1  field applies a torque to 
!
M , causing it to 
rotate about 
!
B1  and into the transverse plane by an amount ", known as the flip angle: 
 
! 
" (t) = # B1(t)0
$
% dt          (1.12) 
 
where 
! 
"  is the duration of the applied B1 field. Since 
!
M  presesses about 
!
B0  at the Larmor 
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frequency (Equation 1.2) as it leaves the z-axis, the applied 
!
B1  must also be precessing at 
! 
" 0  
to remain perpendicular to 
!
M  as it rotates down into the transverse plane. Figure 1.1 shows 
the net magnetization rotating into the transverse plane in a frame of reference (
! 
x ' ,y ' ,z') that 
rotates at 
! 
" 0  about the 
! 
z = z' axis. In this rotating frame of reference, 
!
B1  is stationary and 
!
M  rotates about 
!
B1  but with no rotation about z ' . 
 
 
Figure 1.1: Signal excitation occurs as the net magnetization 
!
M  is rotated by the flip angle 
! 
"  
about 
!
B1 , producing magnetization in the
! 
x and y  directions, Mx  and My . 
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The gyromagnetic ratio for a proton is 42.576 MHz/T. Human MR systems have static 
magnetic field strenths (B0) on the order of one to several Tesla resulting in precession 
(Larmor) frequencies of protons in the radiofrequency (RF) range (Equation 1.2). Therefore 
RF pulses are used to generate the B1 fields used for excitation. Conventional RF pulses are 
applied at a constant frequency (Larmor frequency) with varying amplitude; known as 
amplitude modulation.  
 Adiabatic RF pulses, which have benefits at high magnetic field (explained in section 
1.4.2), are both frequency and amplitude modulated. When adiabatic RF pulses are played 
out, they begin with the pulse frequency (
! 
" RF (t)) far from the Larmor frequency (
! 
" 0). The 
frequency is then gradually changed over time to match the nuclear precession frequency. 
The difference between the frequency of the RF pulse and the Larmor frequency is !!(t) : 
 
!!(t) =!0 "!RF (t)           (1.13) 
 
and can be represented by a fictitious field in the z direction. The magnetic field (B1(t)) that 
produces the adiabatic pulse in the transverse plane can be aligned with the 
! 
x ' axis in a frame 
of reference that rotates at the instantaneous frequency of the pulse (
! 
" RF (t)) about the z axis. 
In this representation, the B1(t) field remains stationary in the reference frame and its 
amplitude can be modulated as illustrated in Figure 1.2. 
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Figure 1.2: The effective field (
!
Beff (t) ) for an adiabatic pulse shown in a frame of reference 
rotating about the 
! 
z  axis at 
! 
" RF (t). Also shown are the!!(t) /"  field arising from the 
frequency modulation, the amplitude modulated field (
! 
"1(t) /# ), and the angle (
! 
"( t)) of the 
rotation of 
!
Beff (t)  from the z-axis. 
 
The total effective field produced, 
!
Beff (t) , is given by the vector sum of B1(t) = 
! 
"1(t) /#  in 
the x’ direction and the fictitious field, !!(t) /" , in the z’ direction (Figure 1.2). At the 
beginning of an adiabatic pulse the frequency offset !!(t)  is large, !!(t) /"  >> B1(t), and 
therefore 
!
Beff (t)  is initially along the z’ direction. As time passes 
! 
"RF  gradually approaches 
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! 
" 0 and !!(t)  approaches zero all while B1(t) becomes larger than !!(t) /" , until B1(t) >> 
!!(t) /"  and !Beff (t)  is swept from being co-linear with z’ to being co-linear with x’ (90° 
roation). A 180° sweep can be achieved by gradually changing 
! 
"RF  from 
! 
" 0  to a large 
negative frequency offset, -!!(t) , until -!!(t) /"  >> B1(t) and 
!
Beff (t)  becomes co-linear 
with -x’. Any magnetization that is collinear with 
!
Beff (t)  at the beginning of the adiabatic 
pulse is locked and rotated through the frequency sweep. To keep the magnetization locked 
to 
!
Beff (t)  the adiabatic condition must be fulfilled throughout the frequency sweep, written 
as: 
 
!Beff (t)>>
d"(t)
dt        (1.14) 
 
where the angle 
!
Beff (t)  makes with the positive z  axis (!(t) ) as illustrated in Figure 1.2 is 
given by: 
 
!(t) = arctan "1(t)
!"(t)
"
#
$
%
&
'           (1.15) 
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1.3.3 Detection 
 Following excitation, the magnetization in the transverse plane precesses about the z  
axis producing a changing magnetic field (
!
B ) in the laboratory reference frame ( x, y, z ). This 
changing magnetic field creates a changing magnetic flux 
! 
"M  through a conductive coil, and 
therefore an electromotive force ( emf ) according to Faraday induction: 
 
emf = ! d"Mdt = !
d
dt area#
!
B $d!a           (1.16) 
 
where   
! 
d! a are the area vectors that are normal to the 
! 
z  axis. The emf creates an alternating 
current in the coil at the Larmor frequency, which is the detected signal. 
 
1.3.4 Relaxation 
 The magnetization following an excitation pulse is described by the Bloch Equation 
(76): 
 
d
!
M
dt = !
!
M !
!
B0 "
Mx
!x +My
!y
T2
"
(Mz "M0 )
!z
T1
     (1.17) 
 
where T2 is the transverse relaxation time constant that describes the decay of the transverse 
magnetization (Mx and My), and T1 is the longitudinal relaxation time constant that describes 
the regrowth of the longitudinal magnetization (Mz). The Bloch Equation can be separated 
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into the following components: 
 
dMx
dt = !MyB0 !
Mx
T2
        (1.18) 
 
! 
dMy
dt
= "#MxB0 "
My
T2
        (1.19) 
 
! 
dMz
dt
= "
Mz " M 0
T1
               (1.20) 
 
and the solutions to Equations 1.18-1.20 are: 
 
Mx (t) = Mx (0)cos(!0t)+My (0)sin(!0t)( )e
!
t
T2    (1.21) 
 
My (t) = !Mx (0)sin(!0t)+My (0)cos(!0t)( )e
!
t
T2   (1.22) 
 
Mz (t) =M0 + Mz (0)!M0( )e
!
t
T1         (1.23) 
 
where time zero is directly after the excitation pulse has been applied. Over time the excited 
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magnetization will return to the initial state (Mz = M0 and Mxy = 0 as t approaches $). The 
regrowth of the longitudinal magnetization (T1 relaxation) is caused by energy exchange 
between the excited nuclei and the surrounding lattice, and is therefore called the spin-lattice 
relaxation time. On the other hand, the loss of phase coherence between nuclei (T2 
relaxation) is caused by energy exchange between spins, and is therefore called spin-spin 
relaxation. Additional spin dephasing introduced by external field inhomogeneities produces 
a loss of coherence of the transverse magnetization that is represented by the time constant 
! 
T2 '. The combined affect of internal spin-spin (
! 
T2) and external field inhomogeneity (
! 
T2 ') 
relaxation mechanisms is given by the time constant 
! 
T2
* : 
 
1
T2*
=
1
T2
+
1
T2 '
             (1.24) 
 
Combined Equation 1.21 and Equation 1.22, and replacing 
! 
T2 with 
! 
T2
*  yields a simplified 
equation for the transverse relaxation: 
 
Mxy (t) =Mxy (0)e
!
t
T2*
              (1.25) 
 
This equation represents the MR signal following excitation and is referred to as the free 
induction decay (FID). Differences in the T1 and T2 relaxation times of biological tissues are 
the source of the contrast observed in MR images. 
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1.3.5 Spatial encoding 
 Linear gradient magnetic fields are applied in the 
! 
z  direction (
! 
Bz) to encode the spatial 
position of spins as follows: 
 
!
G(!r ) = dBzd!r                      (1.26) 
 
where   
! 
! r  is in the direction of the linear 
! 
Bz  variation. Applying such a linear gradient field 
can induce a spatially dependent phase: 
 
!(t) = "
!
G(!r,# ) ! !rd
0
t
" #                   (1.27) 
 
where t  is the duration of the applied gradient field. This gradient spatial encoding allows 
the MR signal produced by the object to be associated with its spatial frequency and encoded 
as a function of k-space, defined as: 
 
!
kr (t) =
!
2"
!
G(!r,# )d
0
t
! #                    (1.28) 
 
and therefore: 
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!(t) = 2"
!
kr !
!r                    (1.29) 
 
The k-space signal represents the Fourier transform of the object. Therefore inverse Fourier 
transform of the k-space data produces the spatial position of the spin signal (the image). 
Phase encoding gradients can be applied following signal excitation and before data 
acquisition so that spins accrue a spatially dependent phase as a function of position in the 
phase-encode direction. Whereas readout gradients are applied during acquisition; the 
frequency of spins is a function of their position and results in a position dependent phase 
accrual in the frequency-encode direction. 
 
1.4  Magnetic resonance spectroscopy (MRS) 
1.4.1 Water suppression 
 Most magnetic resonance imaging techniques applied to humans measure the signal 
from water protons (1H) resonating at a single frequency. The high concentration of water in 
the human body (e.g. approximately 45 mol/L in human brain grey matter and 40 mol/L in 
white matter (77)) allows the acquisition of high resolution images in short scan time. 
Magnetic resonance spectroscopy (MRS) is related technique designed to simultaneously 
detect multiple signals resonating at different frequencies. Human brain tissue contains 
numerous mobile metabolites with protons that resonance at specific frequencies depending 
on their unique chemical environments. In human brain the concentration of water (~50x103 
mmol/L) is approximately four orders of magnitude larger than the concentrations of 
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metabolites (~1-10 mmol/L). The large water signal overlaps with the much smaller 
metabolite signals, making it difficult to identify metabolite peaks. Further, the large 
difference in signal amplitudes between water and metabolites creates dynamic range 
problems for the MR system receivers, resulting in baseline distortions that affect metabolite 
peaks. Therefore, suppression of the signal from water protons is paramount to the reliable 
detection and quantification of metabolite signals. 
 The most common approach to suppress the water signal takes advantage of the 
chemical shift difference between water and metabolite signals, as water resonances at 4.7 
ppm and most metabolites of interest resonate between 1.3 and 4.1 ppm (ppm - parts per 
million frequency shift from a reference standard). Chemical shift selective (CHESS) pulses 
(78) are most often used to selectively suppress the water signal. This technique uses a 
selective RF pulse to rotate the longitudinal magnetization of the water protons into the 
transverse plane (excitation), then a B0 magnetic field gradient dephases the magnetization to 
destroy the water signal. Excitation of the metabolite signals is performed immediately after 
dephasing the water signal, significantly reducing the contribution of water to the metabolite 
spectrum. 
 Ideally, the CHESS pulse will rotate all of the water magnetization by 90° into the 
transverse plane, so that complete dephasing of the water signal may occur. However, B0 and 
B1 inhomogeneities will affect the flip angle leaving some magnetization in the longitudinal 
direction when the dephasing gradient is applied. The magnetization left in the longitudinal 
direction will produce a visible signal in the metabolite spectrum. For this reason, in practice 
multiple CHESS pulses and dephasing gradients are used to destroy the water signal before 
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metabolite detection. Variable Power and Optimized Relaxation delays (VAPOR) is a 
common water suppression scheme that uses seven CHESS pulses with specific relative 
amplitudes and inter-pulse timings to suppress water magnetization equally for flip angles 
ranging from 65° to 125° (79). 
 
1.4.2 Signal localization 
 Region specific metabolite levels are of interest in various diseases. MRS localization 
methods include single voxel spectroscopy and spectroscopic imaging (MRSI); the remainder 
of this thesis will only deal with single voxel 1H spectroscopy (MRS). A common method 
used to localize metabolite signals to a specific voxel in the tissue uses three RF pulses 
applied with orthogonal magnetic field gradients. The two most common 1H MRS sequences 
are stimulated echo acquisition mode (STEAM) (80) and point resolved spectroscopy 
(PRESS) (81), which both measure signal echoes. A traditional spin echo is formed when a 
180° inversion pulse is applied a duration of time (TE/2, where TE is the echo time) after an 
excitation pulse. The inversion pulse inverts all spins and causes the spins that have gained 
and lost phase due to their differences in local magnetic fields to now lose and gain phase, 
respectively. This results in a refocused signal maximum at TE, called the spin echo. 
 A STEAM sequence consists of three orthogonal slice selective 90° RF pulses with the 
following inter-pulse timings (90° - TE/2 - 90° - TM - 90° - TE/2 - echo) where TM is the 
mixing time. This sequence produces a signal echo called a stimulated echo (82), and its 
signal originates from the intersection of  the three slice selection slabs. The background 
signals from unwanted echoes are eliminated with crusher gradients applied after each 90° 
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pulse. There are three advantages of STEAM: (i) very short echo times can be achieved as 
90° pulses can be shorter than 180° pulses and TM interval does not contribute to the echo-
time, (ii) 90° pulses typically have sharper edge profiles than 180° pulses resulting in more 
accurate signal localization, and (iii) 90° pulses require less power than 180° pulses, 
important for SAR considerations, particularly at high magnetic fields. The major 
disadvantage of STEAM is a 2-fold decrease in the stimulated echo signal as compared to a 
traditional spin echo. This signal loss occurs because the second 90° pulse only rotates half 
of the dephased transverse magnetization into the longitudinal direction to be stored there 
during the TM interval. The other half of the magnetization that remains in the transverse 
plane is dephased during the TM interval. 
 A PRESS sequence consists of one 90° RF pulse followed by two 180° RF pulses, 
applied during orthogonal magnetic field gradients to localize the signal. The first 180° pulse 
creates a traditional spin echo that is subsequently refocused by the second 180° pulse (as 
long as the time between the 180° pulses is longer than the time between the 90° pulse and 
the first 180° pulse), creating the spin echo that is detected. The 180° RF pulses used in 
PRESS are generally longer than 90° pulses used in STEAM making short TEs more 
difficult, increasing power deposition, and degrading slice selection profiles. However, the 
detected spin echo has twice the signal magnitude compared to the STEAM induced 
stimulated echo, which can be very important due to the inherent low signal intensities of 
brain metabolites. 
 Both STEAM and PRESS are susceptible to B1 and B0 inhomogeneities that can lead to 
non-ideal excitation and incomplete signal refocusing. B1 inhomogeneities cause spins to 
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experience different B1 fields and therefore different flip angles, whereas B0 inhomogeneities 
cause dephasing of the spins that can not be refocused by the subsequent refocusing pulses. 
Also common to STEAM and PRESS protocols is the use of outer volume suppression 
(OVS) to minimize signals arising from outside the volume of interest. However, OVS can 
decrease the SNR of metabolites within the measurement volume due to magnetization 
transfer effects (83). 
 Localization by adiabatic selective refocusing (LASER) is another MRS localization 
sequence but unlike STEAM and PRESS, LASER is insensitive to B1 and B0 
inhomogeneities. As suggested in the name, LASER utilizes adiabatic RF pulses (84) that are 
insensitive to B1 and B0 inhomogeneities. Another advantage of adiabatic pulses is their 
excellent slice selection profiles, sharper than traditional pulses, negating the need for OVS 
(85). Therefore, the LASER sequence is ideal for in vivo experiments where inhomogeneities 
are present, and for high field strength applications where achieving B1 uniformity is more 
challenging. The LASER sequence consists of a global adiabatic half passage (AHP) pulse 
for non-selective excitation of the entire volume, followed by three pairs of orthogonal slice 
selective adiabatic full passage (AFP) inversion pulses. Each pair of AFP pulses refocuses 
the magnetization within a slab, and the three intersecting slabs define the 3D voxel from 
where the detected signal originates. The phase evolution that occurs during the first AFP in 
each pair is refocused by the second AFP (85), resulting in a spin echo. Each one of the six 
AFP pulses in LASER is surrounded by symmetric crusher gradients to destroy any coherent 
magnetization outside of the selection volume; these crusher gradients help achieve sharp 
slice profiles. There are two major disadvantages of the LASER sequence. First, longer TEs 
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are required due to the larger number of pulses. Second, short duration adiabatic pulses 
require high amplitude RF pulses that may be limited by the maximum available amplifier 
output and result in higher power deposition potentially exceeding SAR limits. Increasing 
pulse length is possible to reduce the maximum required B1 at the expense of increasing 
echo-time. 
 
1.4.3 Chemical shift 
 Electrons surrounding nuclei are charged particles in motion and therefore create their 
own magnetic field, resulting in a reduction (or shielding) of the static magnetic field (B0). 
The altered magnetic field (B) experienced by the nucleus is given by: 
 
! 
B = B0 (1 "#)                    (1.30) 
 
where !  is the shielding coefficient, which has dimensionless units of ppm and is 
independent of B0. The chemical environment determines the electron distribution 
surrounding the nucleus and subsequently the magnitude of the shielding coefficient. The 
reduction in magnetic field experienced by the nucleus results in a lower precession 
frequency, conventionally termed a chemical shift in frequency. The chemical shift (
! 
" ) also 
has dimensionless units of ppm and is given by: 
 
! 
" =
f # f ref
fref
$10 6               (1.31) 
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where f  is the frequency of the nucleus of interest and fref  is the frequency of a nucleus in 
a reference compound (ie. proton MRS commonly uses sodium 3-trimethylsilyl-propionic 
acid (TSP) as a chemical shift reference). With MRS the unique chemical shifts in frequency 
produced by electronic shielding are used to identify signals from nuclei in specific 
molecules. 
 
1.4.4 J-coupling 
 Some compounds contain nuclear spins that have complex spectral patterns due to a 
phenomenom known as J-coupling or spin-spin coupling. J-coupling refers to an interaction 
between non-identical nuclear spins within a molecule through the electrons of covalent 
bonds, resulting in slight frequency shifts. Figure 1.3a shows the chemical structure of 
lactate, and Figure 1.3b illustrates the splitting of the peaks from the interaction between 
methyl and methine protons. 
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Figure 1.3: The chemical structure (a) and J-coupling spectral pattern (b) for lactate. The one 
proton on the second carbon (methine group) and the three protons on the third carbon 
(methyl group) are J-coupled. The three protons of the methyl group are magnetically 
equivalent and split the signal from the methine proton into a quartet at 4.2 ppm with a 
1:3:3:1 ratio in amplitudes. The single methine proton splits each methyl proton into a 
doublet at 1.3 ppm with a 1:1 amplitude ratio. Although its not shown as such, the total area 
of the methyl peaks is three times the total area of the methine peaks because the methyl 
group has three times as many protons generating the single. 
 
 
Without J-coupling there would be one methine proton peak and one methyl proton peak, but 
in reality these peaks are split as illustrated in Figure 1.3b. The frequency peak of a spin is 
split according to the spin orientation of the non-identical spin or spins it is coupled to. In the 
example of lactate (Figure 1.3b), the three identical methyl protons are split into two peaks of 
equal area because the spin of the single coupled methine proton is either parallel or up (low 
energy state) or antiparallel or down (high energy state) with the static magnetic field. The 
single methine proton is split into four peaks with relative areas in a 1:3:3:1 ratio because it is 
coupled to three methyl protons with four possible spin configurations: (up, up, up) one way, 
(up, up, down) three ways, (up, down, down) three ways, and (down, down, down) one way. 
In general, a J-coupled nucleus will be split into 
! 
n +1 peaks from 
! 
n magnetically equivalent 
nuclei, and the amplitudes of the split peaks are given by Pascal’s triangle (e.g. 1:1, 1:2:1, 
1:3:3:1, etc.). The frequency difference between the split peaks is defined by the J-coupling 
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constant in units of Hz, and is the same for each of the coupled nuclei. J-coupling is 
undesirable in MRS since the would-be single large peak is spread out into multiple smaller 
peaks, decreasing the SNR and creating complex overlapping within in vivo spectra. Also, J-
coupling can act as a source of transverse relaxation, further hindering the SNR of the J-
coupled peaks. 
 
1.4.5 Multiple receiver signal combination 
 A phased-array radiofrequency (RF) coil is comprised of N coil elements that 
independently detect the MR signal, resulting in N FIDs per acquisition. The FIDs can be 
combined as described by Brown et al (86) using three properties of each coil element n: a 
sensitivity weighting factor (wn), a proximity weighting factor (an), and a phase factor (!n). 
The sensitivity weighting factors (wn) are calculated as: 
 
! 
wn =
"n
"1
2 +"2
2 + ...+"n
2             (1.32) 
 
where "n is the standard deviation of the noise in each element measured using the tail-end of 
each FID. The proximity weighting factors (an) are simply the maximum amplitudes of the 
FID from each coil element, normalized by the amplitude of the largest FID. The phase 
compensation factors (#!n) are calculated as: 
 
! 
"#n = #n $#ref       (1.33) 
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where !n is the phase of the first complex data point of each FID and !ref is an arbitrarily 
chosen reference phase. The combined signal S(t): 
 
! 
S(t) = wnane
" i#$ n Sn (t)( )n
N%       (1.34) 
 
is given by the weighted sum of the coil element signals Sn(t). 
 
1.5  MRS spectral quantification 
1.5.1 Lineshape corrections 
 The net transverse magnetization induces a sinusoidally varying current in the receiver 
coil at the Larmor frequency that decays exponentially due to transverse relaxation. 
Following Fourier transform this signal produces a Lorentzian lineshape in the frequency 
domain. However, lineshape distortions arise from magnetic field (B0) inhomogeneities and 
induced eddy currents (87,88) leading to non-Lorentzian lineshapes in the frequency-domain 
signal and errors in spectral peak area estimations when fitting with Lorentzian lineshapes 
(77,89,90). Two popular methods used to correct lineshape distortions are the QUALITY 
(QUAntification improvement by converting LIneshapes to the lorentzian TYpe) 
deconvolution (91) and eddy current correction (ECC) (88). QUALITY deconvolution 
consists of dividing the time-domain signal by a reference time-domain signal that has 
experienced the same B0 inhomogeneities, typically the unsuppressed water signal, restoring 
Lorentzian lineshapes. However, the T2 of water in the brain is shorter (~50 ms, (92)) than 
! 37 
the T2 of most metabolites (~300 ms, (93)), leading to large signal spikes towards the end of 
the corrected time-domain signal because of division by near-zero water signal values. Eddy 
currents induced by magnetic field gradients produce time-dependent shifts of the resonance 
frequency, also resulting in distortion of the spectrum in the frequency domain (88). ECC is 
performed in the time domain by subtracting the phase of a reference signal (unsuppressed 
water) that has undergone the same distortions, from the phase of the signal to be corrected. 
However, ECC only corrects for B0(t) distortions and therefore does not fully restore the 
Lorentzian lineshape. Bartha et. al. (94) combined QUALITY deconvolution and ECC 
(QUECC) to produce lineshape-corrected data without signal spikes by performing 
QUALITY deconvolution on the initial portion of the time-domain data followed by ECC on 
the remaining data points. 
 
1.5.2 Echo time considerations 
 Most clinical studies use long echo time (TE > 100 ms) MRS to detect changes in N-
acetylaspartate (NAA), total creatine (tCr), and choline (Cho = GPC + PC). Long-TE spectra 
(e.g. TE = 135 ms, 270 ms) are relatively simple to analyze as they contain easily resolved 
peaks from NAA, tCr, and Cho and few overlapping signals from macromolecules (95). In 
contrast, acquisition with short-TE (TE < 50 ms) produces visible peaks from additional 
metabolites including glutamate (Glu), glutamine (Gln), and myo-inosital (mI) as well as 
broad peaks from macromolecules. Metabolite quantification then becomes more difficult 
due to the overlapping macromolecule resonances that extend beneath the 2-4 ppm 
metabolite region and overlap with several metabolites of interest (e.g. Glu, Gln, and tCr) 
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(95). Short-TE MRS is able to detect more metabolite signals for two reasons. First, the 
signals from species with short T2 relaxation times have not appreciably decayed, and 
second, signal loss from J-coupling phase modulation is reduced. 
 
1.5.3 Macromolecule removal 
 One approach to account for the macromolecule contribution is to include prior 
information about the macromolecule lineshapes in the fitting (79). However, macromolecule 
resonances have been shown to fluctuate in disease conditions (96), potentially leading to 
inaccurate metabolite measurements (97). 
 Alternatively, a subject-specific macromolecule spectrum can be acquired in addition 
to the metabolite spectrum and subsequently used to subtract the macromolecule 
contributions from the metabolite spectrum (97). Although this approach increases 
acquisition time, it provides the most direct method to identify subject specific 
macromolecule contributions. A macromolecule spectrum, free of metabolite signals, can be 
directly measured by inversion-nulling the metabolite signals (98,99). Inversion-nulling 
refers to applying a 180° pulse followed by a specific time delay (TI), defined by the T1 of 
the signal to be nulled, before the 90° excitation pulse rotates the magnetization into the 
transverse plane for detection. The longitudinal magnetization following a 180° pulse is:  
 
! 
Mz( t) = M0 1" 2e
" tR1( )      (1.35) 
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obtained by setting Mz(0) = - M0 and substituting into Equation 1.23.  At 7T the longitudinal 
relaxation times (T1 = 1/R1) of macromolecules (T1 ~ 430 ms) are shorter than metabolites 
(T1 ~ 1600 ms) (100,101). Therefore the magnetization from the macromolecule protons 
relaxes back along the longitudinal axis more quickly than that from the metabolite protons, 
as illustrated in Figure 1.4. 
 
 
 
Figure 1.4: Longitudinal magnetization for macromolecules and metabolites following a 180° 
inversion pulse. The T1s of macromolecules are shorter (~350 ms at 7T) than metabolites 
(~1200 ms at 7T), and therefore the macromolecule magnetization realigns with the 
longitudinal axis much more quickly than the metabolite magnetization. Applying a 90° 
excitation pulse at tnull will rotate magnetization from the macromolecules into the transverse 
plane, allowing the direct measurement of the macromolecule signals without overlapping 
metabolite signals.  
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Setting the delay time (TI) equal to the time where the magnetization from the metabolite 
protons crosses zero (tnull) will result in no excitation of the metabolite signals when the 90° 
pulse is applied, in theory producing a pure macromolecule spectrum. The macromolecule 
spectrum can then be subtracted from the full spectrum (containing metabolite and 
macromolecule signals) to produce a macromolecule-free metabolite spectrum as illustrated 
in Figure 1.5. One advantage of macromolecule measurement and subtraction is that the 
resulting metabolite only spectrum will be void of complicating macromolecule resonances. 
An advantage for acquiring a macromolecule spectrum alongside each full spectrum, as 
opposed to using a generalized macromolecule baseline function in the fitting, is that 
macromolecule removal will be more accurate in cases where the macromolecule baseline 
fluctuates. Disadvantages of this approach to remove macromolecule resonances include: a 
nearly two-fold increase in MRS scan time, and the macromolecule subtraction introduces 
some error in the resulting metabolite spectrum peaks. 
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Figure 1.5: The full spectrum containing both metabolite and macromolecule signals, the 
macromolecule spectrum with metabolites suppressed, and the resulting metabolite spectrum 
following macromolecule subtraction. 
 
 
1.5.4 Fitting to metabolite prior knowledge 
 The area under a peak in a MR spectrum is directly proportional to the number of 
nuclei resonating at that particular frequency, and therefore also proportional to the number 
of molecules in which the nuclei originate. As a result, the concentration of a molecule can 
be determined from the area of the associated resonance peak or peaks. Integration over the 
! 42 
width of a peak in the frequency domain is the simplest approach to determine the area of a 
peak, but this approach not practical for in vivo short echo-time 1H MRS data due to the 
overlapping of metabolite peaks. Further, although the time and frequency domain 
representations contain identical information due to the linearity of the Fourier transform 
(FT), in practice the frequency domain data may have severe artifacts such as baseline 
distortions caused by truncation of the FID in the time domain. Therefore, quantitative 
analyses of metabolite spectra are often performed in the time domain to avoid any 
distortions induced by the FT of the data. One approach to the analysis of short echo-time 1H 
MRS data involves the use of metabolite lineshapes. The incorporation of such prior 
knowledge obtained from in vitro metabolite solutions greatly simplifies spectral fitting. 
Spectra are reconstructed using linear combinations of known metabolite lineshapes to 
determine the contribution of each to the in vivo spectrum. Figure 1.6 shows a typical in vivo 
1H MR spectrum acquired from healthy human brain at 7T, along with the fitted 
contributions from the major metabolites of interest. 
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Figure 1.6: A typical 7T in vivo 1H MR spectrum from healthy human brain with 
superimposed fit in orange (a), residual difference between the data and fit (b), and individual 
metabolite components from NAA (c), Glu (d), Gln (e), tCr (f), Cho (g), and mI (h). 
 
 The lineshape of each metabolite to be included in the in vivo fitting template can be 
obtained from fitting a high-resolution in vitro spectrum (77,91) acquired from an aqueous 
solution of that respective metabolite, described in detail by Bartha et. al. (89). Sodium 3-
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trimethylsilyl-propionic acid (TSP) is used as a chemical shift and Lorentzian damping 
reference (89) for each metabolite lineshape. This metabolite fitting method has been 
successfully demonstrated by several groups at field strengths ranging from 1.5T to 9.4T 
(79,96-99,101-104), however it is only accurate when all contributions to the in vivo 
spectrum are incorporated during fitting (101). 
 Prior knowledge metabolite templates can be fitted to MRS data by minimizing the 
difference between the reconstructed spectrum and the data using a Levenberg-Marquardt 
algorithm for nonlinear least squares optimization (105). The nth point of the reconstructed 
FID is given by (106): 
 
! 
xn = Amei(" 0 +"1,m )e#(R2,m + i$wm )tn
m
M
%
          (1.36) 
 
where M is the total number of sinusoids. Equation 1.36 describes each resonance (m, peak 
in the spectrum) with the following parameters: amplitude (Am), frequency-independent zero-
order phase (
! 
"0 ), frequency-dependent first-order phase (
! 
"1,m ), transverse decay rate 
(
! 
R2,m =1/T2,m), and chemical shift (
! 
"#m =#m $# 0). In the fitting template each resonance’s 
chemical shift and Lorentzian damping are linked to common parameters using the TSP 
reference, and relative amplitudes of different resonances from the same metabolite are 
linked to each other. Linking these parameters both simplifies the fitting by reducing the 
number of parameters to vary and ensures proper classification of each resonance as the 
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chemical shifts and relative amplitudes are fixed. Only the relative amplitudes from 
difference metabolites are allowed to vary. 
 
1.5.5 Signal relaxation corrections 
 Accurate quantification of metabolite levels from in vivo spectra requires amplitude 
corrections that incorporate the different relaxation times (T1 and T2) of water and metabolite 
protons. For instance, during the time between excitation and the formation of the spin echo 
(TE), signals from water protons decay more than signals from metabolite protons because of 
their shorter T2s, and these differences must be accounted for when attempting to measure 
absolute metabolite levels. Similarly, differences in T1 values between water and metabolites 
result in different amounts of longitudinal relaxation between consecutive MRS scans, and 
must be accounted for before absolute quantification. Further complicating relaxation 
correction is the fact that relaxation times vary with tissue type. As an example, water at 4T 
has T1 values of 1348 ms and 904 ms and T2 values of 70 ms and 55 ms in GM and WM, 
respectively (106). Errors in metabolite level measurement may arise when incorporating 
relaxation correction due to the uncertainty in T1 and T2 time constants. These values are 
often difficult to measure for all metabolites, and additionally, pathological conditions can 
alter the normal T1 and T2 values. The use of pulse sequences with short echo-times and long 
repetition times minimizes these errors caused by these uncertainties. 
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1.5.6 Partial volume correction 
 The water content within the MRS measurement volume can be used as an internal 
reference (107,108) as the concentration of water is well known within brain tissue 
(77,107,108). However, the accurate quantification of metabolite concentrations then 
requires measurement of tissue partial volume within the voxel as each tissue type has a 
specific water concentration. One approach to determine the proportions of cerebral spinal 
fluid (CSF), grey matter (GM), and white matter (WM) is to segment (109,110) high 
resolution anatomical images acquired during the same imaging session. The proportions of 
each tissue type, along with their respective water concentrations, are then used to assign the 
correct concentration to the reference water signal. 
 Another approach to estimate voxel CSF content is to collect a series of water spectra 
at a range of echo times to measure the water signal transverse decay. This approach can 
separate the water decay data into CSF (T2 = 141 ms at 7T (92)) and tissue (GM + WM) 
components (at 7T, T2GM  = 50 ms, T2WM = 55 ms (92)), to give the proportions of CSF and 
tissue water within the voxel (Figure 1.7). Since the T2 values of GM and WM are so close, 
this method cannot reliably separate the components of GM and WM and therefore they are 
combined into the tissue component. The ideal approach would be to correct for signal 
relaxation effects by separating GM and WM components because of their differences in T1 
and T2 values. However, this method yields accurate results because the signal attenuation 
corrections for GM and WM (using TR, TE, T1, and T2 values) do not differ substantially 
(<5% at 7T with TR/TE = 3700/38 ms). 
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Figure 1.7: Representative plot of normalized water signal versus echo time (TE), with 
superimposed two-component exponential decay fit. The individual contributions from CSF 
and tissue are also shown, illustrating their initial water signal amplitudes and decay rates. 
 
This separation is accomplished by acquiring water spectra at a range of TEs and then fitting 
the data to a two-component exponential decay equation: 
 
S(TE) = S0 + ACSF exp !
TE
T2,CSF
"
#
$$
%
&
''+ Atissue exp !
TE
T2,tissue
"
#
$$
%
&
''                (1.37) 
 
where ACSF and Atissue are the initial amplitudes of the CSF and tissue signals, respectively. In 
the example shown in Figure 1.7 there is more tissue in the MRS measurement volume than 
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CSF. In this case, the tissue water signal is initially large but decays more quickly due to its 
shorter T2 (~50 ms) than CSF (~150 ms) (92). 
 
1.6  Thesis overview 
 This introductory chapter provided an overview of the neuropathology, current 
diagnosis, and current treatment of Alzheimer disease. Secondly, current neuroimaging 
methods used to study AD were presented, along with a detailed description of the major 
metabolic changes as measured by proton magnetic resonance spectroscopy (1H MRS). 
Lastly, pertinent principles of magnetic resonance (MR), MR imaging, and MR spectroscopy 
were presented, with a detailed description of the steps involved in MRS data acquisition, 
post-processing, and quantification. 
 Chapter 2 presents a short echo time LASER 1H MRS study at 4T where metabolite 
concentrations were measured in subjects with AD following four months of galantamine 
treatment. Chapter 3 presents a long echo time PRESS 1H MRS study at 3T where metabolite 
concentrations were measured in subjects with AD following four months of rivastigmine 
treatment. Chapter 4 presents the details of a short echo-time semi-LASER 1H MRS data 
acquisition and quantification protocol at 7T, incorporates subject-specific macromolecule 
removal, to determine absolute metabolite levels in the human brain. Chapter 5 will provide a 
summary of this thesis, and will describe future work and limitations of this research. 
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Chapter 2 
 
Increased glutamate in the hippocampus after 
galantamine treatment for Alzheimer disease 
 
 A version of this chapter has been previously published. Penner J, Rupsingh R,  Smith 
M, Wells JL, Borrie MJ, Bartha R. Increased glutamate in the hippocampus after 
galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 
2010; 34(1): 104-110. 
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2.1  Introduction 
 Alzheimer Disease (AD) is the most common form of dementia and it is a progressive, 
degenerative disease of the brain resulting in cognitive and memory impairments. The 
clinical progression of AD is currently measured by cognitive assessments, most commonly 
using the Mini-Mental State Examination (MMSE) (1) or the Alzheimer Disease Assessment 
Scale-cognitive subscale (ADAS-cog) (2,3). However, these cognitive assessments offer 
modest sensitivity at best (2,4,5), particularly in early stages of the disease. In an effort to 
improve monitoring of disease progression and response to treatment, various non-invasive 
imaging methods are under development. 
 One such biomarker for disease status is proton magnetic resonance spectroscopy (1H 
MRS), which can be used to measure several metabolites in the human brain.  Although the 
neurochemical abnormalities of AD assessed by 1H MRS are not completely defined, there is 
evidence of progressive chemical changes that involve multiple brain regions. These changes 
include decreased N-acetylaspartate (NAA) or NAA/total creatine (tCr = Cr + PCr) in the 
parietal and occipital cortex (6), gray matter (7,8), hippocampus (9-11), and posterior 
cingulate (12) as well as increased myo-inositol (mI) in parietal and occipital cortex (6), gray 
matter (7), and posterior cingulate (12).  Since NAA is a marker of neuronal integrity or 
viability, these studies consistently demonstrate loss of neuronal function in subjects with 
AD.  The increase in mI is associated with gliosis (13).  The tCr concentration is typically 
used as a stable relative control value. 
 Previous studies performed at magnetic field strengths of ! 3 Tesla (T) have also noted 
changes in glutamate (Glu) + glutamine (Gln) concentration, commonly reported as Glx.  Glu 
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is a major excitatory neurotransmitter that has been shown to decrease with age in control 
subjects (14), while Gln is a precursor of Glu. Glu excitotoxicity is a feature of AD (15), 
therefore it is becoming increasingly important to understand how this metabolite could be 
used as a marker of disease progression and response to therapy.  Previous studies have 
reported decreased Glx or Glx/tCr ratio in subjects with AD compared to control subjects in 
occipital gray matter (7), in the cingulate cortex (16), and in the posterior cingulate gyrus and 
precuneus (17).  Decreased Glx levels have also been reported over approximately 12 months 
in the posterior cingulate gyrus in subjects with mild cognitive impairment (MCI) (18). 
 1H MRS has successfully been used to evaluate AD progression (11,19) and response 
to treatment (20-22).  However 1H MRS treatment response studies have been limited to 
donepezil (20,21) and rivastigmine (22), two acetylcholinesterase inhibitors (AChEI) in 
clinical use that have been shown to provide symptomatic relief for mild to moderate AD 
(23) and increase glucose metabolism (24).  A third approved treatment, galantamine (Gal), 
has yet to be studied by 1H MRS.  Gal inhibits acetylcholinesterase (AChE) activity, but also 
acts as an allosteric potentiating ligand for presynaptic nicotinic acetylcholine receptors 
(nAChR) (25).  In the hippocampus, this modulatory function may facilitate glutamatergic 
neurotransmission resulting in beneficial effects on learning and memory.  This increase in 
glutamatergic transmission may lead to increases in intracellular Glu levels detectable by 1H 
MRS.  In addition, Gal may prevent Glu neurotoxicity leading to neuronal apoptosis (26).  
Therefore it is of particular interest to determine whether Gal modulates Glu levels following 
treatment. 
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 As technology improves and the use of high magnetic field strength (" 3 T) magnetic 
resonance imaging (MRI) becomes more accessible, 1H MRS spectra can be acquired with a 
greater signal-to-noise ratio and improved spectral resolution (3,27,28), generally improving 
overall metabolite quantification.  We have previously shown that the use of short echo-time 
1H MRS at 4 T in combination with advanced metabolite quantification methods can be used 
to measure Glu levels in the hippocampus (20,29).  The hippocampus is of particular interest 
as it is known to be involved early in the pathogenesis of AD.   In a recent study using 4T 1H 
MRS, we found that glutamate levels were decreased in the right hippocampus in subjects 
with AD compared to normal elderly controls (30).  Based on this result and the mechanism 
of action of Gal, we hypothesized that 4 months of Gal treatment would result in detectable 
changes in the 1H MRS metabolite profile measured from within the right hippocampus of 
patients with AD, specifically that levels of Glu would increase due to increased 
glutamatergic neurotransmission.  The right hippocampus was chosen to allow a direct 
comparison with a previous study by our group examining metabolite level changes 
following donepezil treatment (20).  Therefore, the purpose of this study was to measure the 
metabolite level changes within the right hippocampus in response to four months of Gal 
treatment using 1H MRS, and to correlate metabolic changes with standard clinical outcomes 
(MMSE and ADAS-cog scores). 
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2.2  Methods 
2.2.1 Patient Population 
 Subjects who met the National Institute of Neurological and Communicative Disorders 
and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA) 
criteria for probable AD were recruited from the Aging Brain and Memory Clinic in London, 
Ontario, Canada. Ten subjects participated in this study, which was approved by the 
University of Western Ontario Health Sciences Research Ethics Board. The MMSE and the 
ADAS-cog were performed on the participants immediately before (baseline) and four 
months after beginning Gal treatment. After the baseline MRI scan, subjects were started on 
galantamine ER 8 mg/day after breakfast for the first month, and then increased to 16 mg/day 
for the remainder of the study. Subjects were maintained on this dose following the post dose 
MRI scan at 4 months. This two-step dosing approach mirrored the same two-step approach 
previously used to study the effects of donepezil (Bartha et al., 2008). Although a maximum 
dose of 24 mg/day is possible with galantamine it may be less well tolerated than 16 mg/day. 
Therefore, a maximum dose of 16 mg/day was chosen to avoid losing subjects for the post-
dose MRI component of this study. Additionally, there is no randomized controlled trial data 
suggesting any statistically significant greater clinical benefit for 24 mg/day compared to 16 
mg/day. It was also considered that most older people have reduced renal function, i.e. 
creatinine clearance of <60 mL/min. 1H MRS was used to measure the concentrations of 
metabolites within the right hippocampus of the participants at baseline and at 4 months. The 
study participant demographics are summarized in Table 2.1. 
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Table 2.1: Demographics of study participants 
 
    Baseline  4 months   p-value#  
 
N    10   10    - 
 
Gender   7F/3M  7F/3M   - 
 
Age (years)   81.5 ± 6.0  81.9 ± 6.0   - 
 
MMSE   25.9 ± 2.0  24.7 ± 1.9 (N = 9) 0.10 (N = 9) 
 
ADAS-cog   15.2 ± 4.2  15.1 ± 6.5 (N = 9) 0.82 (N = 9) 
 
Education (years)  12.9 ± 3.8  -    - 
 
N - number of participants, F - female, M - male 
Age, MMSE, ADAS-cog, and Education values listed as average ± standard deviation. 
# - p-values for two-tailed repeated measures t-tests 
 
 
2.2.2 Assessment Instruments 
 All images and 1H MR spectra were acquired using a Varian (Palo Alto, CA) whole 
body 4 T MRI scanner with a Siemens (Erlangen, Germany) Sonata gradient coil.  At the 
start of each study, a series of images were acquired parallel to the hippocampus (Figure 2.1) 
using a 3D inversion prepared T1-weighted Fast Low Angle Shot (FLASH) imaging 
sequence (TI/TR/TE = 500/9.5/5 ms, 256x256 slice resolution, 16 slices, 2.5 mm thickness, 
FOV = 24 cm) for placement of the 1H MRS voxels. 1H MRS data were acquired as 
previously described (29,30) from a voxel ranging in volume from 2.8 cm3 to 4.7 cm3 
(average ± standard deviation = 3.5 ± 0.6 cm3) positioned within the right hippocampus 
(Figure 2.1). 
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Figure 2.1: Transverse oblique T1-weighted FLASH image (FOV = 22 cm, slice thickness = 
2 mm, TI/TR/TE = 500/9.5/5 ms) of a patient with Alzheimer disease acquired parallel to the 
hippocampus on a Varian/Siemens 4T MRI system. The spectroscopy voxel outlined in white 
is positioned within the right hippocampus. 
 
The spectroscopy acquisition utilized variable pulse power and optimized relaxation delays 
(VAPOR) water suppression (31) followed by short echo-time (TE/TR = 46/3200 ms) 
localization by adiabatic selective refocusing (LASER, 2 kHz receiver bandwidth, #cp = 6 ms) 
(32).  For each scan, a full spectrum (containing both the metabolite and macromolecule 
signals), a macromolecule spectrum (metabolite suppressed macromolecule signal), and a 
water spectrum (containing the unsuppressed water signal) were acquired (29).  Metabolite 
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suppression was achieved by two-pulse inversion nulling (33), using adiabatic full passage 
(HS2-R10) pulses (TI1 = 2.20 s, TI2 = 0.69 s).  The resulting spectra were lineshape corrected 
(34) to eliminate eddy current distortions.  The macromolecule spectrum was fit using an 
automated Hankel singular value decomposition (HSVD) fitting routine (29,35) and scaled 
by 1.2 to account for T1-saturation before subtracting it from the full spectrum.  Any 
remaining unsuppressed water signal was then removed by subtracting resonances between 
4.1 and 5.1 parts per million (ppm) (water ~ 4.7 ppm) as determined by the HSVD algorithm 
(29). 
 
2.2.3 Data analysis 
 Metabolite levels were quantified by fitting the resultant metabolite spectra in the time 
domain (fitMAN software (36)) using a Levenberg-Marquardt minimization routine (37) 
incorporating prior knowledge from 19 metabolite lineshapes as previously described 
(29,30,36).  Metabolite levels were normalized to the unsuppressed water level and then 
corrected for T1 and T2 relaxation effects (29,30,38).  The water content was estimated to be 
81% in the hippocampus and 71% in the white matter (39,40).  Table 2.1 in Kassem and 
Bartha (29) lists the T1 and T2 values for water and the metabolites of interest in gray matter 
and white matter of young healthy subjects at 4 T.  These same values were used in the 
current study for subjects with AD except the T2 of water was reduced by 15% to 86 ms 
based on the results of Haley et al (41) in subjects with AD.  No adjustment was made for the 
T2 of the metabolites as it has been shown that the T2 of several metabolites are the same for 
young controls and subjects with AD (7). 
                                                                                                                
 
68 
 Measured metabolite concentrations were also corrected for the amount of cerebral 
spinal fluid (CSF) contained in the measurement voxel.  The relative amounts of gray matter, 
white matter and CSF in each voxel were determined by segmenting the T1-weighted 3D 
FLASH images (Figure 2.1) using statistical parametric mapping (14) in a program called 
SPM5 (42,43).  To achieve consistent segmentation each image was transformed onto a 
template using a rigid body transformation before the segmentation was performed and a 
template of tissue probability was utilized.  The contribution of gray matter, white matter, 
and CSF to each voxel in normal tissue was calculated using a plug-in written in ImageJ 
(National Institute of Health). 
 The metabolites NAA, Glu, tCr, choline (Cho = GPC + PC), and mI were included in 
statistical comparisons based on previous studies that have implicated these metabolites in 
AD pathophysiology, and because these metabolites could be reliably measured.  Paired two-
tailed repeated measures t-tests were used to compare baseline and 4 month absolute 
metabolite concentrations.  In a secondary analysis the ratios of NAA/tCr, Glu/tCr, 
Glu/NAA, and Glu/mI were also compared, as were the MMSE and ADAS-cog scores.  A 
Bonferroni correction was applied to the comparison of absolute metabolite levels and 
metabolite ratios.  In the case of absolute metabolite levels, the corrected p-value for 
significance was p < 0.01 (5 comparisons made), while for the metabolite ratios the corrected 
p-value for significance was p < 0.0125 (4 comparisons).  P < 0.05 was used for comparison 
of cognitive scores.  Linear regression analysis was performed comparing the change in 
metabolite levels with the change in cognitive scores. 
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2.3  Results 
 Figure 2.1 shows a typical image used in positioning the MRS voxel, shown as a gray 
box, within the right hippocampus.  Figure 2.2 shows the spectrum acquired from one subject 
at baseline along with the fitted result and the residual (the difference between the fit and the 
spectrum). 
 
 
Figure 2.2: The individual spectra representing NAA (A), Glu (B), tCr (C), Cho (D), and mI 
(E) are shown beneath the acquired magnetic resonance spectrum (in gray) and the fitted 
result (black, F). The residual (G) is the difference between the acquired spectrum and the fit 
result. 
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The individual metabolite components for NAA, Glu, tCr, Cho, and mI that contributed to 
the spectrum are also provided in Figure 2.2.  In the voxels studied, the average proportions 
of gray matter, white matter, and cerebral spinal fluid were 54%, 27%, and 19% respectively 
at baseline and 54%, 26%, and 20% respectively at 4 months. 
 The average absolute metabolite levels at baseline and 4 months are shown in Figure 
2.3. Glu increased by 35% (p < 0.01), while NAA, tCr, Cho, and mI did not change 
significantly. 
 
 
Figure 2.3: Average absolute metabolite concentrations at baseline (BL) and after 4 months 
(4m) of galantamine treatment in the same patients. The errors bars represent the standard 
deviation, and the asterisk represents a significant difference between baseline and 4 months 
(p < 0.01). 
The average metabolite ratios at baseline and 4 months are shown in Figure 2.4.  The ratio of 
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Glu/tCr increased by 46% (p < 0.01) and Glu/NAA increased by 54% (p < 0.001). 
 
 
Figure 2.4: Average metabolite ratios at baseline (BL) and after 4 months (4m) of 
galantamine treatment in the same patients. The error bars represent the standard deviation, 
and single and double asterisks represent significant differences between baseline and 4 
months with p < 0.01 and p < 0.001, respectively. 
 
Interestingly, the change ($) in Glu ($Glu) correlated with the $NAA (Figure 2.5, p < 0.05), 
although NAA did not change significantly. 
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Figure 2.5: The association between the change in N-acetylaspartate and the change in 
glutamate. The black line represents the linear fit to the data. 
 
 The average MMSE and ADAS-cog scores at baseline and 4 months are provided in 
Table 2.1.  The 4 month cognitive scores of one subject were excluded from the analysis as 
this individual had an uncharacteristic lack of interest during this testing session resulting in 
poor scores that improved a few months after treatment with donepezil and venlafaxine.  
Although the 4 month cognitive scores from this subject were excluded from the analysis, the 
subject’s MRS data was included in the analysis as the MRS levels are the primary measure 
of this study and would not likely be effected by the lack of interest of an individual. The 
MMSE and ADAS-cog scores and the ratio of Glu/mI showed no change between baseline 
and 4 months, however the change in the ratio of Glu/tCr ($(Glu/tCr)) was correlated with 
                                                                                                                
 
73 
the change in the MMSE scores ($MMSE) (Figure 2.6, p < 0.05), and the change in the ratio 
of Glu/mI ($(Glu/mI)) was inversely correlated with the change in the ADAS-cog scores 
(Figure 2.7, p < 0.05). 
 
 
Figure 2.6: The association between the change in the ratio of Glu/tCr and the change in 
MMSE scores. The black line represents the linear fit to the data. 
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Figure 2.7: The association between the change in the ratio of glutamate/myo-inositol and the 
change in ADAS-cog scores. The black line represents the linear fit to the data. 
 
2.4  Discussion 
 The purpose of this study was to measure metabolite level changes within the right 
hippocampus of newly diagnosed subjects with AD in response to four months of Gal 
treatment using 1H MRS, and determine if these changes correlated with changes in cognitive 
function measured using MMSE or ADAS-cog scores.  Absolute Glu levels were found to 
increase in subjects with AD following 4 months of Gal treatment, as did the ratios of 
Glu/tCr and Glu/NAA. 
 Although several studies have shown changes in metabolite concentrations in AD, few 
studies have examined treatment response (summarized in Table 2.2). 
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Table 2.2: Summary of previously reported treatment effects 
 
Study Treatment Interval Location   Findings 
 
Bartha Don  16 weeks Right hippocampus Decreased NAA, NAA/tCr, & 
et al, 2008         mI/tCr compared to baseline 
 
Jessen Don  12 weeks Parietal lobe  Correlation of $NAA and  
et al, 2006         $NAA/tCr with $ADAS-cog 
 
Krishnan Don  12 & 18 Periventricular  Increased NAA compared to 
et al, 2003   weeks white matter  control 
 
    12 weeks Subcortical   Increased NAA compared to 
      gray matter   control 
 
Modrego Riv    16 weeks Frontal cortex  Increased NAA/tCr compared 
et al, 2006         to baseline 
 
    16 weeks Occipital cortex  Increased mI/tCr compared 
          to baseline 
 
Don - donepezil, Riv - rivastigmine 
 
Decreased NAA or NAA/tCr and increased mI have been reported most consistently in 
subjects with AD that are not receiving treatment (6-12).  Of the few studies that have 
examined treatment effects, one study found a correlation between changes in NAA and 
NAA/tCr with changes in ADAS-cog in the parietal lobe after 12 weeks of donepezil 
treatment (44).  A second study found a higher concentration of NAA in subjects who 
received donepezil treatment than those who received placebo at 12 and 18 weeks in the 
periventricular matter and at 12 weeks in the subcortical gray matter (21). A previous study 
by our group using the same methodology as the current study showed decreased NAA and 
NAA/tCr levels as well as mI/tCr levels, and no change in Glu levels in the right 
hippocampus after 4 months of donepezil treatment (20). These metabolic changes indicate 
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continued neuronal impairment following treatment, although the change in mI/tCr was 
attributed to an effect of the medication since mI is normally increased in AD.  A fourth 
study showed increased NAA/tCr in the frontal cortex and increased mI/tCr in the occipital 
cortex after 4 months of rivastigmine treatment (22).  The variability in these previous 
studies may indicate a differential effect of brain region.  The current study is the first to 
report metabolite changes associated with Gal treatment and did not show an alteration in 
either NAA levels, mI/tCr levels, or average cognitive scores over four months. 
 Gal is expected to exert effects on the glutamatergic system.  However, the 
measurement of tissue Glu levels by 1H MRS requires the use of short-echo time acquisitions 
and advanced quantification methods (29,30,35).  The use of magnetic field strengths of < 3 
T also makes it difficult to separate overlapping resonances in the spectrum from Glu and 
Gln, resulting in the common reporting of a combined Glu plus Gln measure called Glx.  A 
few previous studies have reported decreased Glx in occipital cortex (7), the cingulate cortex 
(16), the gray matter of the posterior cingulated gyrus and precuneous (17), and no change in 
the midfrontal and temperoparietal gray matter (45) in subjects with AD.  Recently, we have 
also shown decreased Glu in the right hippocampus in subjects with AD (30).  These studies 
are supported by a study in a non-treated transgenic AD mouse model that showed a decrease 
in Glu in progressive AD (46).  One might expect decreased Glu along with decreased NAA 
as they both exist mainly in neuronal pools and neuronal degradation is consistently reported 
in progressive AD.  However, the finding of the current study indicating increased Glu 
following Gal treatment suggests that measured Glu levels may be related to 
neurotransmission and cognitive function. A post-hoc analysis also found no differences in 
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glutamine levels (data not shown) in the current study following treatment, providing further 
support for the observed changes in glutamate (since glutamate and glutamine resonances 
overlap in the 1H spectrum).  The observed positive correlation between the change in 
Glu/tCr and the change in MMSE score, and the inverse correlation between the change in 
Glu/mI and the change in ADAS-cog score suggest that these metabolite ratios are related to 
cognitive function and performance. 
 It has been reported that Gal improves cognitive functions in subjects with AD by 
increasing the activity of the cholinergic system (23).  Neurotransmission within the 
hippocampus involves the interaction of both glutamatergic and cholinergic signal 
transduction mechanisms.  AChEIs reduce the breakdown of acetylcholine thereby increasing 
cholinergic neurotransmission.  Gal is unique among AChEIs approved for treatment of AD 
as it is a weak cholinesterase inhibitor, but is efficiently able to allosterically stimulate %7 
nAChRs (47-49).  The %7 nAChR is an ion channel found in high concentration in the 
hippocampus that allows entry of 2+Ca into the cell (50,51).  Gal binds to nAChRs and acts as 
an allosteric potentiating ligand, sensitizing the receptor to activation by acetylcholine, which 
in turn stimulates glutamatergic release (48).  The increase in Glu release stimulates post-
synaptic N-methyl-D-aspartic acid (NMDA) receptors and produces beneficial effects on 
learning and memory.  Thus the increase in Glu observed in the hippocampus in the current 
study may be related to the action of Gal as an allosteric potentiating ligand for %7 nAChRs.  
Activation of %7 nAChRs by Gal may also prevent Glu neurotoxicity (52-54) and the 
subsequent apoptosis of neurons containing Glu, which could also result in a higher Glu 
concentration. 
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 Although this study includes a small sample size of ten subjects, the statistical power 
associated with the change in absolute Glu concentration is 0.94.  Further limitations of this 
study include only measuring the right hippocampus over a short follow-up time of 4 months.  
Although the short follow-up time may be considered an advantage from the point-of-view of 
the metabolite measurements, it may contribute to learning effects associated with the 
cognitive assessment.  Such a learning effect may contribute to a false positive response.  
However, there is sufficient evidence in the cholinesterase inhibitor literature when using the 
ADAS-cog as a measure of cognition in patients with dementia to justify reliable results 
within a timeframe of 4 months (55-57).  Nonetheless, the significant increase in absolute 
Glu indicates that Glu levels may be an important metabolite marker in assessing AD 
progression and response to treatment.  Although further studies are needed, non-invasive 
metabolite measurements could be used in conjunction with clinical markers of cognition, 
function, and behavior, to verify treatment response. 
 
2.5  Conclusions 
 Short echo time 1H magnetic resonance spectroscopy at 4 Tesla was used to measure 
metabolite concentrations within the right hippocampus of 10 subjects with AD following 
four months of galantamine treatment.  The absolute Glu concentration increased, as did the 
ratios of Glu/tCr and Glu/NAA.  The change in the ratio of Glu/tCr was positively correlated 
with the change in the MMSE scores and the change in the ratio of Glu/mI was inversely 
correlated with the change in the ADAS-cog scores, both suggesting that these metabolite 
ratios are related to cognitive function.  Further studies are required to determine whether the 
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increase in Glu continues with galantamine treatment during further disease progression. 
                                                                                                                
 
80 
2.6  References 
1. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for 
grading the cognitive state of patients for the clinician. Journal of psychiatric research 
1975;12(3):189-198. 
2. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. The 
American journal of psychiatry 1984;141(11):1356-1364. 
3. Bartha R, Drost DJ, Menon RS, Williamson PC. Comparison of the quantification 
precision of human short echo time (1)H spectroscopy at 1.5 and 4.0 Tesla. Magn Reson 
Med 2000;44(2):185-192. 
4. Anthony JC, LeResche L, Niaz U, von Korff MR, Folstein MF. Limits of the 'Mini-
Mental State' as a screening test for dementia and delirium among hospital patients. 
Psychological medicine 1982;12(2):397-408. 
5. Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial 
MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging 
1997;7(6):1069-1075. 
6. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: 
depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 
1993;187(2):433-437. 
7. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations 
in patients with probable Alzheimer disease. Magn Reson Med 1994;32(1):110-115. 
8. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal 
decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 
2000;355(9216):1696-1697. 
9. Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer 
JH, Mastrianni JA, Fein G, Weiner MW. Changes of hippocampal N-acetyl aspartate and 
volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. 
Neurology 1997;49(6):1513-1521. 
10. Block W, Jessen F, Traber F, Flacke S, Manka C, Lamerichs R, Keller E, Heun R, Schild 
H. Regional N-acetylaspartate reduction in the hippocampus detected with fast proton 
                                                                                                                
 
81 
magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Archives 
of neurology 2002;59(5):828-834. 
11. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD. Longitudinal quantitative 
proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. 
Brain 2002;125(Pt 10):2332-2341. 
12. Kantarci K, Jack CR, Jr., Xu YC, Campeau NG, O'Brien PC, Smith GE, Ivnik RJ, Boeve 
BF, Kokmen E, Tangalos EG, Petersen RC. Regional metabolic patterns in mild 
cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 
2000;55(2):210-217. 
13. Ross BD. Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; 
myo-inositol and related metabolites. NMR in biomedicine 1991;4(2):59-63. 
14. Schubert F, Gallinat J, Seifert F, Rinneberg H. Glutamate concentrations in human brain 
using single voxel proton magnetic resonance spectroscopy at 3 Tesla. NeuroImage 
2004;21(4):1762-1771. 
15. Glodzik L, King KG, Gonen O, Liu S, De Santi S, de Leon MJ. Memantine decreases 
hippocampal glutamate levels: a magnetic resonance spectroscopy study. Progress in 
neuro-psychopharmacology & biological psychiatry 2008;32(4):1005-1012. 
16. Antuono PG, Jones JL, Wang Y, Li SJ. Decreased glutamate + glutamine in Alzheimer's 
disease detected in vivo with (1)H-MRS at 0.5 T. Neurology 2001;56(6):737-742. 
17. Hattori N, Abe K, Sakoda S, Sawada T. Proton MR spectroscopic study at 3 Tesla on 
glutamate/glutamine in Alzheimer's disease. Neuroreport 2002;13(1):183-186. 
18. Olson BL, Holshouser BA, Britt W, 3rd, Mueller C, Baqai W, Patra S, Petersen F, 
Kirsch WM. Longitudinal metabolic and cognitive changes in mild cognitive impairment 
patients. Alzheimer disease and associated disorders 2008;22(3):269-277. 
19. Kantarci K, Xu Y, Shiung MM, O'Brien PC, Cha RH, Smith GE, Ivnik RJ, Boeve BF, 
Edland SD, Kokmen E, Tangalos EG, Petersen RC, Jack CR, Jr. Comparative diagnostic 
utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. 
Dementia and geriatric cognitive disorders 2002;14(4):198-207. 
20. Bartha R, Smith M, Rupsingh R, Rylett J, Wells JL, Borrie MJ. High field (1)H MRS of 
the hippocampus after donepezil treatment in Alzheimer disease. Progress in neuro-
psychopharmacology & biological psychiatry 2008;32(3):786-793. 
                                                                                                                
 
82 
21. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, 
Ieni JR, Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on 
neuronal markers and hippocampal volumes in Alzheimer's disease. The American 
journal of psychiatry 2003;160(11):2003-2011. 
22. Modrego PJ, Pina MA, Fayed N, Diaz M. Changes in metabolite ratios after treatment 
with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic 
resonance spectroscopy. CNS drugs 2006;20(10):867-877. 
23. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane database of 
systematic reviews (Online) 2006(1):CD005593. 
24. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM. 
Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer 
disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr 
Psychiatry 2003;11(2):169-177. 
25. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates 
nicotinic receptors: effects on the course of Alzheimer's disease. Biological psychiatry 
2001;49(3):289-299. 
26. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A. 
Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent 
glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-
kinase cascade. Neuropharmacology 2006;51(3):474-486. 
27. Tkac I, Andersen P, Adriany G, Merkle H, Ugurbil K, Gruetter R. In vivo 1H NMR 
spectroscopy of the human brain at 7 T. Magn Reson Med 2001;46(3):451-456. 
28. Kantarci K, Reynolds G, Petersen RC, Boeve BF, Knopman DS, Edland SD, Smith GE, 
Ivnik RJ, Tangalos EG, Jack CR, Jr. Proton MR spectroscopy in mild cognitive 
impairment and Alzheimer disease: comparison of 1.5 and 3 T. Ajnr 2003;24(5):843-
849. 
29. Kassem MN, Bartha R. Quantitative proton short-echo-time LASER spectroscopy of 
normal human white matter and hippocampus at 4 Tesla incorporating macromolecule 
subtraction. Magn Reson Med 2003;49(5):918-927. 
30. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R. Reduced hippocampal glutamate 
in Alzheimer disease. Neurobiology of aging 2009. 
                                                                                                                
 
83 
31. Tkac I, Starcuk Z, Choi IY, Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1 
ms echo time. Magn Reson Med 1999;41(4):649-656. 
32. Garwood M, DelaBarre L. The return of the frequency sweep: designing adiabatic pulses 
for contemporary NMR. J Magn Reson 2001;153(2):155-177. 
33. Knight-Scott J. Application of multiple inversion recovery for suppression of 
macromolecule resonances in short echo time (1)H NMR spectroscopy of human brain. J 
Magn Reson 1999;140(1):228-234. 
34. Bartha R, Drost DJ, Menon RS, Williamson PC. Spectroscopic lineshape correction by 
QUECC: combined QUALITY deconvolution and eddy current correction. Magn Reson 
Med 2000;44(4):641-645. 
35. van den Boogaart A, Ala-Korpela M, Jokisaari J, Griffiths JR. Time and frequency 
domain analysis of NMR data compared: an application to 1D 1H spectra of 
lipoproteins. Magn Reson Med 1994;31(4):347-358. 
36. Bartha R, Drost DJ, Williamson PC. Factors affecting the quantification of short echo in-
vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR in 
biomedicine 1999;12(4):205-216. 
37. Marquardt DW. An Algorithm for Least-Squares Estimation of Nonlinear Parameters. 
Journal of the Society of Industrial and Applied Mathemathics 1963;11(2):431-441. 
38. Isobe T, Matsumura A, Anno I, Yoshizawa T, Nagatomo Y, Itai Y, Nose T. 
Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy 
using T2 relaxation time correction. Magnetic resonance imaging 2002;20(4):343-349. 
39. Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HB. In vivo 
quantification of brain metabolites by 1H-MRS using water as an internal standard. 
Magnetic resonance imaging 1993;11(1):107-118. 
40. Kaiser LG, Schuff N, Cashdollar N, Weiner MW. Age-related glutamate and glutamine 
concentration changes in normal human brain: 1H MR spectroscopy study at 4 T. 
Neurobiology of aging 2005;26(5):665-672. 
41. Haley AP, Knight-Scott J, Fuchs KL, Simnad VI, Manning CA. Shortening of 
hippocampal spin-spin relaxation time in probable Alzheimer's disease: a 1H magnetic 
resonance spectroscopy study. Neuroscience letters 2004;362(3):167-170. 
                                                                                                                
 
84 
42. Ashburner J, Friston K. Multimodal image coregistration and partitioning--a unified 
framework. NeuroImage 1997;6(3):209-217. 
43. Wright IC, McGuire PK, Poline JB, Travere JM, Murray RM, Frith CD, Frackowiak RS, 
Friston KJ. A voxel-based method for the statistical analysis of gray and white matter 
density applied to schizophrenia. NeuroImage 1995;2(4):244-252. 
44. Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W. Treatment monitoring 
and response prediction with proton MR spectroscopy in AD. Neurology 
2006;67(3):528-530. 
45. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early 
Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 
1997;203(3):829-836. 
46. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG. Magnetic resonance 
spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human 
APP shows altered neurochemical profile. Brain research 2004;1012(1-2):60-65. 
47. Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque 
EX, Maelicke A. Galantamine is an allosterically potentiating ligand of the human 
alpha4/beta2 nAChR. Acta neurologica Scandinavica 2000;176:68-73. 
48. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, 
Albuquerque EX. The nicotinic allosteric potentiating ligand galantamine facilitates 
synaptic transmission in the mammalian central nervous system. Molecular 
pharmacology 2002;61(5):1222-1234. 
49. Woodruff-Pak DS, Vogel RW, 3rd, Wenk GL. Galantamine: effect on nicotinic receptor 
binding, acetylcholinesterase inhibition, and learning. Proceedings of the National 
Academy of Sciences of the United States of America 2001;98(4):2089-2094. 
50. Albuquerque EX, Pereira EF, Mike A, Eisenberg HM, Maelicke A, Alkondon M. 
Neuronal nicotinic receptors in synaptic functions in humans and rats: physiological and 
clinical relevance. Behavioural brain research 2000;113(1-2):131-141. 
51. Radcliffe KA, Fisher JL, Gray R, Dani JA. Nicotinic modulation of glutamate and 
GABA synaptic transmission of hippocampal neurons. Annals of the New York 
Academy of Sciences 1999;868:591-610. 
                                                                                                                
 
85 
52. Geerts H. Indicators of neuroprotection with galantamine. Brain research bulletin 
2005;64(6):519-524. 
53. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for 
stroke and traumatic brain injury? Lancet neurology 2002;1(6):383-386. 
54. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators 
for the treatment of CNS disorders. Current drug targets 2004;3(3):181-194. 
55. Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Attainment of treatment goals 
by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. 
Cmaj 2006;174(8):1099-1105. 
56. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month 
randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 
Study Group. Neurology 2000;54(12):2261-2268. 
57. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of 
galantamine in probable vascular dementia and Alzheimer's disease combined with 
cerebrovascular disease: a randomised trial. Lancet 2002;359(9314):1283-1290. 
 
 
86 
 
Chapter 3 
 
Reduced N-acetylaspartate to creatine ratio in the 
posterior cingulate correlates with cognition in Alzheimer 
disease following four months of rivastigmine treatment 
 
 A version of this chapter has been accepted for publication. Penner J, Wells JL, Borrie 
MJ, Woolmore-Goodwin SM, Bartha R. Reduced N-acetylaspartate to creatine ratio in the 
posterior cingulate correlates with cognition in Alzheimer disease following four months of 
rivastigmine treatment. Dement Geriatr Cogn Disord. Accepted August 19, 2014. 
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3.1  Introduction 
 Alzheimer disease (AD) is a neurodegenerative disease characterized by a progressive 
loss in memory, language, executive, and visuospatial functions. Cognitive assessments are 
predominantly used to monitor the clinical progression of AD (1,2). These assessments offer 
modest sensitivity to AD (2-4), but lack specificity (2-4). Brain imaging has also been 
intensively studied in the context of Alzheimer’s disease in an effort to find a biomarker that 
will improve the evaluation of disease progression. Methods include structural magnetic 
resonance imaging (MRI) (5-9), functional MRI (fMRI) (10-12), fluorodeoxyglucose 
positron emission tomography (FDG-PET) (13-15), amyloid PET (16-18), and cerebral blood 
flow single photon emission computed tomography (CBF-SPECT) (19). However, objective 
and rapid evaluation of treatment response using non-invasive imaging requires further 
development to direct treatment decisions that could postpone decline in cognitive 
performance. 
The standard of care for patients with AD is treatment with a cholinesterase inhibitor 
(ChEI) (20,21). The ChEIs currently in clinical use are rivastigmine, donepezil, and 
galantamine. ChEIs have been developed based on the cholinergic hypothesis (22), which 
proposes that AD involves reduced synthesis of acetylcholine, which leads to reduced 
cholinergic neurotransmission from neurons originating in the basal forebrain (23,24). 
Treatment with rivastigmine produces positive effects on cognitive performance and 
activities of daily living in patients with AD (25-28). In a meta-analysis of all three second-
generation ChEIs (27), donepezil and galantamine showed similar cognitive efficacy to 
rivastigmine, but rivastigmine is the only ChEI that is available as a transdermal patch. 
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Previous studies have reported that transdermal administration reduces gastrointestinal 
adverse events (29), provides sustained therapeutic drug plasma levels (30), and is preferred 
over capsules by 70% of caregivers due to ease of use (31). 
To optimize patient care, rapid assessment of treatment response is needed. Although 
not considered disease modifying, ChEIs can induce metabolic changes in the brain 
measurable by proton magnetic resonance spectroscopy (1H MRS) (32-38). 1H MRS is a non-
invasive imaging technique capable of directly detecting mobile metabolites in the human 
brain with concentrations greater than approximately 0.5 mM (39). There is mounting 
evidence of neurochemical abnormalities, assessed by 1H MRS, in multiple brain regions in 
AD (40-46). 1H MRS studies of treatment response have investigated donepezil (32,35), 
rivastigmine (37), and galantamine (38). Metabolite level changes have been reported in 
multiple brain regions following ChEI treatment (summarized in Table 3.1). However, only 
one study to date has measured the effects of rivastigmine, which was performed at 1.5 Tesla 
and examined the frontal, parietal, and occipital cortices (37). This previous study found 
increased NAA/tCr in the frontal cortex that correlated with ADAS-cog scores, increased 
mI/tCr in the occipital cortex, and no changes in cognitive scores after four months of 
rivastigmine treatment (37). 
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Table 3.1: Summary of previously reported ChEI treatment effects 
 
Study  ChEI N Int. Location  Findings    Interpolated 
    (w)         !NAA/tCr  
             over 4 months 
 
Henigsberg Don 12 26 Dorsolateral  Increased NAA/tCr vs baseline +4.0% 
et al., 2011    prefrontal cortex 
 
Modrego Don 32 26 Bilateral PC  Increased NAA/tCr vs baseline +1.3% 
et al., 2010    Left occipital  Increased mI/tCr vs baseline 
     Right prefrontal Increased mI/tCr vs baseline 
     Left prefrontal Decreased NAA/tCr vs baseline -1.8% 
 
Penner  Gal 10 16 Right hipp  No change in NAA/tCr  N.C. 
et al., 2010       Increased Glu & Glu/tCr vs baseline 
        !Glu/tCr correlated with !MMSE 
 
Bartha  Don 10 16 Right hipp  Decreased NAA, NAA/tCr,  -16% 
et al., 2008       & mI/tCr vs baseline 
 
Jessen  Don  17 12 Parietal lobe  No change in NAA/tCr  N.C. 
et al., 2006       !NAA & !NAA/tCr correlated 
        with !ADAS-cog 
 
Modrego Riv 24 16 Frontal cortex  Increased NAA/tCr vs baseline +5.7% 
et al., 2006    Occipital cortex Increased mI/tCr vs baseline 
 
Krishnan Don 28 12&18 Periventricular Increased NAA vs control  N.C. 
et al., 2003    white matter  
    12 Subcortical  Increased NAA vs control 
     gray matter 
 
ChEI - cholinesterase inhibitor, N - number of participants, Int. - treatment interval (weeks), 
! - change in, Don - donepezil, PC - posterior cingulate, Gal - galantamine, hipp - 
hippocampus, Riv- rivastigmine, N.C. - no change over time 
 
The posterior cingulate is of particular interest in AD for several reasons. First, 
cholinergic axons, implicated in the pathology of AD, project directly from the basal 
forebrain to the posterior cingulate cortex (24,47-49). Second, the posterior cingulate is a site 
of known pathology including neuronal loss (50,51) and "-amyloid accumulation (52). 
Furthermore, numerous imaging modalities have reported changes in the posterior cingulate 
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in AD patients, including MRS (36,46,53-55), PET (52), and fMRI blood flow (56). Finally, 
the location of the posterior cingulate within the brain makes it amenable to the acquisition of 
high quality 1H MRS data (57). As high magnetic field strength (# 3T) magnetic resonance 
imaging (MRI) systems become more accessible 1H MRS spectra can be acquired with 
greater signal-to-noise ratio and improved spectral resolution (58-60), increasing the 
sensitivity of this technique. 
  The purpose of this study was to determine whether four months of rivastigmine 
treatment would alter metabolite levels measured by 1H MRS in the bilateral posterior 
cingulate cortex of subjects with AD, and to correlate metabolic changes with standard 
cognitive assessment scores. Based on previous studies, we hypothesized that four months of 
rivastigmine treatment would result in increased levels of NAA and NAA/tCr measured from 
the bilateral posterior cingulate cortex of patients with AD. 
 
3.2  Method 
3.2.1 Patient population 
 This study was approved by the Western University Health Sciences Research Ethics 
Board. Sixteen subjects were recruited from the Aging Brain and Memory Clinic in London, 
Ontario, Canada. All subjects were newly diagnosed with probable AD using the National 
Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and 
Related Disorders Association (NINCDS/ADRDA) criteria. Nine subjects had at least one 
vascular risk factor including six with hypertension, eight with hyperlipidemia, and one with 
diabetes; all were stable on medication. All participants gave written informed consent. At 
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follow-up, one subject received a new diagnosis of Primary Progressive Aphasia and was 
removed from the study. The data from another subject was not included in the analysis 
because their 1H MRS spectrum at follow-up had insufficient signal-to-noise ratio (SNR < 5). 
Of the fourteen subjects (70.4 ± 9.3 years of age, 12 right handed, 7/7 female/male) included 
in the analysis, thirteen were diagnosed with mild AD and one with moderate AD at baseline. 
Cognitive testing included the Mini-Mental State Examination (MMSE) (1), the Alzheimer 
Disease Assessment Scale-cognitive subscale (ADAS-cog) (2), and the neuropsychiatric 
inventory (NPI) (61), and were administered to the participants immediately before (baseline) 
and four months after beginning rivastigmine treatment via the transdermal patch. All subject 
and caregiver dyads were instructed on the location of patch application based on the 
standard product monograph and reported toleration and daily compliance. After the baseline 
cognitive tests and MRI scan session were completed, subjects were started on the 
rivastigmine patch (4.6 mg/24 hours for the first month, 9.5 mg/24 hours thereafter). This 
two-step dosing approach mirrored the same two-step approach previously used to study the 
effects of donepezil (32) and galantamine (38). 1H MRS was used to measure the 
concentrations of metabolites within the bilateral posterior cingulate cortex of all subjects at 
baseline and again after four months of treatment. Table 3.2 summarizes the study participant 
demographics. A non-treatment AD control group was not included in this study because as 
recommended at the Third Canadian Consensus Conference on Diagnosis and Treatment of 
Dementia (3rd CCCDTD, 2006), “provision of the best standard of care for the patient must 
always remain the priority” (62), and therefore withholding the standard treatment was 
deemed unethical. Instead, we used previously reported metabolite level longitudinal 
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measurements in AD patients that were drug naïve or stable on medication to compare to our 
cohort. 
 
Table 3.2: Study participant demographic data and cognitive test scores 
 
    Baseline   4 months  p-value#  
 
N    14    14   - 
 
Gender   7F/7M   7F/7M  - 
 
Age (years)   70.4 ± 9.3   70.7 ± 9.3  - 
 
Education (years)  13.9 ± 2.1   -   - 
 
AD severity  13 mild/1 moderate -   - 
 
Family history of AD 10 yes/4 no   -   - 
 
Vascular risk factors 9 yes/ 5 no   -   - 
 
Concomitant meds 10 yes/4 no   -   - 
 
MMSE   24.9 ± 3.6   25.1 ± 3.3  0.74 
 
ADAS-cog   20.4 ± 12.7   19.1 ± 13.0  0.49 
 
NPI    4.8 ± 6.6   6.1 ± 7.3  0.30 
 
Age, Education, MMSE, ADAS-cog, and NPI values listed as mean ± standard deviation 
# - p-values for two-tailed repeated measures t-tests 
N - number of participants, F - female, M - male 
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3.2.2 Magnetic resonance imaging and spectroscopy 
 All imaging and 1H MR spectroscopic data were acquired using a 3T Siemens 
Magnetom Tim Trio whole-body MRI with a 12-channel head coil. Sagittal T1-weighted 3D 
magnetization prepared rapid gradient echo (MPRAGE) (1x1x1.2 mm3, TR/TE = 2300/2.86 
ms, TI = 900 ms) images (Figure 3.1a) and axial T2-weighted 2D turbo spin-echo (TSE) 
(0.9x0.9x3 mm3, TR/TE = 3000/99 ms) images (Figure 3.1b) were acquired for each scan 
and were subsequently used for 1H MRS voxel (measurement volume) placement. 
 
 
Figure 3.1: Sagittal T1-weighted 3D MPRAGE (1x1x1.2 mm3, TR/TE/TI = 2300/2.86/900 
ms) image (a) and axial T2-weighted 2D TSE (0.9x0.9x3 mm3, TR/TE = 3000/99 ms) image 
(b) of a subject with Alzheimer disease acquired on a Siemens 3T MRI system. The 1H MRS 
voxel (white box) is positioned over the bilateral posterior cingulate cortex. 
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Single-voxel 1H MRS data were acquired from a 2x2x2 cm3 volume of interest in the 
bilateral posterior cingulate cortex (Figure 3.1) at baseline and after four months of 
treatment. A point resolved spectroscopy (PRESS) (TR/TE = 2000/135 ms) sequence was 
used to localize 1H MRS data acquisition, which included 192 water suppressed averages and 
8 unsuppressed averages for each scan. Data were lineshape corrected using the QUECC 
method (63), to correct for eddy current and magnetic field inhomogeneity distortions. Any 
remaining unsuppressed water signal present in the suppressed spectrum was removed by 
subtracting resonances between 4.1 and 5.1 parts per million (ppm) (water ~ 4.7 ppm) as 
determined by an automated Hankel singular value decomposition (HSVD) algorithm (64). 
 
3.2.3 Data analysis and statistics 
 The resulting water-removed metabolite spectra were fitted using a Levenberg-
Marquardt minimization routine in the time domain (fitMAN software (65)), which 
incorporated a template of prior knowledge of metabolite lineshapes as previously described 
(64,65). N-acetylaspartate (NAA), glutamate (Glu), glutamine (Gln), total creatine (tCr = Cr 
+ PCr), choline (Cho = GPC + PC), and myo-inositol (mI) were included in the fitting 
template because previous studies have implicated these metabolites in AD pathophysiology, 
and because these metabolites could be reliably measured. The concentrations of NAA, Glx 
(Glu+Gln), tCr, Cho, and mI and the ratios of NAA/tCr, Glx/tCr, Cho/tCr, and mI/tCr were 
calculated and included in the statistical analysis. Ratios relative to tCr were included as they 
are commonly reported in the literature and may be sensitive indicators when the two 
metabolites in the ratio are changing in opposing directions. Also, ratios are not vulnerable to 
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measurement errors caused by imperfect partial volume and relaxation corrections (34). 
Absolute metabolite levels were calculated by scaling the metabolite spectral areas to 
the unsuppressed water signal within the voxel and correcting signal amplitudes for T1 and T2 
relaxation as previously described (64). Water content was estimated as 81% in gray matter 
and 71% in white matter (66). In the current study the proportion of gray matter, white 
matter, and cerebral spinal fluid within the 1H MRS measurement volume was determined by 
segmenting the T1-weighted MPRAGE images using FMRIB’s Automated Segmentation 
Tool (FAST) (67) available in FMRIB’s Software Library (FSL) (68-70). 
Paired two-tailed repeated measures t-tests were used to compare baseline and four month 
concentrations of NAA, Glx, tCr, Cho, and mI as well as ratios of NAA/tCr, Glx/tCr, 
Cho/tCr, and mI/tCr, and the MMSE, ADAS-cog, and NPI scores. For all concentrations, 
ratios, and cognitive scores, significance was established at p < 0.05. Furthermore, 
correlation analysis was used to compare baseline concentrations and ratios to baseline 
cognitive scores and changes in cognitive scores, and to compare the change in 
concentrations and ratios to the change in cognitive scores. All statistical tests were 
performed in Prism (GraphPad Software, Inc., Version 6.0c, La Jolla, CA). 
 
3.3  Results 
 The study participant demographics and clinical data are summarized in Table 3.2. 
There were no significant differences in average MMSE, ADAS-cog, or NPI scores between 
baseline and 4-month follow-up testing sessions. Water and metabolite (water-suppressed) 
spectra were successfully acquired at baseline and at 4-month follow-up in fourteen subjects. 
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Figure 3.1 shows typical sagittal and axial images used to position the 1H MRS voxel over 
the bilateral posterior cingulate cortex. The metabolite spectrum acquired from one subject at 
baseline is shown in Figure 3.2, along with the fitted result and the residual difference 
between the fit and the data. Figure 3.2 also shows the individual spectral components of 
NAA, Glu, Gln, tCr, Cho, and mI that contributed to the fitted spectrum. The average 
proportions of gray matter, white matter, and cerebral spinal fluid within the 1H MRS 
measurement volumes were 48.2%, 26.2%, and 25.7% respectively at baseline and 49.8%, 
25.6%, and 24.6% respectively at four months. There were no statistical differences in these 
values between baseline and 4-month follow-up. 
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Figure 3.2: A representative baseline spectrum from one subject with Alzheimer disease, 
with the fitted result (black line) superimposed unto the acquired data (in gray). The residual 
difference between the data and the fit is shown above the spectrum, and the individual 
metabolite spectra are shown beneath. 
 
There were no significant differences in average metabolite concentrations between baseline 
and 4-month measurements (Figure 3.3). 
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Figure 3.3: Average metabolite concentrations at baseline (BL) and after four months (4m) of 
rivastigmine treatment in 14 patients with Alzheimer disease. Error bars represent the 
standard error of the mean. 
 
Average metabolite ratios normalized to tCr are shown in Figure 3.4, for baseline and 4-
month measurements. The NAA/tCr values were normally distributed, as determined by a 
D’Agostino-Pearson omnibus normality test, permitting the use of a repeated measures t-test 
to compare metabolite values between time points. The ratio of NAA/tCr decreased by 
12.7% (t = -3.274, df = 13, p <0.01) between baseline and 4-month 1H MRS scans, while no 
other ratio changed significantly. 
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Figure 3.4: Average metabolite ratios at baseline (BL) and after four months (4m) of 
rivastigmine treatment in 14 patients with Alzheimer disease. Error bars represent the 
standard error of the mean. 
 
 There were no significant correlations between any baseline metabolite concentration 
or ratio and any baseline cognitive score, or between any baseline metabolite concentration 
or ratio and any change in cognitive score. However, over the four months of treatment, 
significant correlations were observed between the change (!) in NAA/tCr and the !MMSE 
(F = 7.38, df = 12, p < 0.05, Figure 3.5a), and between !Glx/tCr and the !MMSE (F = 7.47, 
df = 12, p < 0.05, Figure 3.5b). 
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Figure 3.5: The associations between the change in the ratio of NAA/tCr and the change in 
MMSE (a), and between the change in the ratio of Glx/tCr and the change in MMSE (b). The 
black lines represent the linear fit to the data. 
 
No other concentration change or ratio change correlated with changes in cognitive score. 
There was also a correlation between !NAA/tCr and !Glx/tCr (F = 6.00, df = 12, p < 0.05, 
Figure 3.6), even though Glx/tCr did not change significantly over four months of treatment. 
 
 
Figure 3.6: The association between the change in the ratio of NAA/tCr and the change in the 
ratio of Glx/tCr. 
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3.4  Discussion 
 The purpose of this study was to measure metabolite levels using 1H MRS within the 
bilateral posterior cingulate cortex in subjects recently diagnosed with AD in response to four 
months of rivastigmine treatment, and to determine whether metabolite levels were correlated 
with cognitive performance. This study is the first to measure the effects of rivastigmine 
treatment on metabolite levels in the posterior cingulate cortex. Although a change in 
cognitive score was not detected across the group, the average ratio of NAA/tCr was found to 
decrease in subjects with AD following four months of rivastigmine treatment. More 
importantly, the change in NAA/tCr over the four months of treatment was positively 
correlated with the change in MMSE score, indicating that there was less of a decline in 
NAA/tCr in subjects with cognitive improvement following treatment compared to subjects 
with cognitive decline. 
Deficits in the cholinergic neurotransmitter acetylcholine (ACh) have been 
consistently reported in AD following the degeneration of cholinergic neurons originating in 
the basal forebrain that project to the cortex and hippocampus (23). The use of ChEI 
treatment generally improves cognitive performance over the first 6-12 months of treatment 
(25-28). For example Wattmo and colleagues measured the cognitive response to ChEI 
treatment in 843 subjects with AD every six months for three years (71). They reported 
cognitive improvement, as measured by the MMSE and ADAS-cog, between zero and six 
months followed by cognitive decline thereafter, indicating that the greatest cognitive 
benefits from ChEIs occur within six months of starting treatment. Therefore it is important 
to rapidly assess therapeutic response so that individual treatment can be optimized.  
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There are currently seven studies in the literature that have reported metabolite level 
changes in subjects with AD in response to ChEI treatment (summarized in Table 3.1). Four 
of these were longitudinal donepezil treatment studies that found: NAA/tCr increased in the 
dorsolateral prefrontal cortex (33) and bilateral posterior cingulate (36); NAA/tCr decreased 
in the left prefrontal region (36) and right hippocampus (32); a correlation between the 
change in NAA and the change in ADAS-cog in the parietal lobe (34); and increased mI/tCr 
in the left occipital lobe and right prefrontal region (36) and decreased mI/tCr in the right 
hippocampus (32). A fifth donepezil study found increased NAA in the periventricular white 
matter and subcortical gray matter in subjects with AD compared to control (35). One 
longitudinal rivastigmine study reported increased NAA/tCr in the frontal cortex and 
increased mI/tCr in the occipital cortex (37). The only longitudinal galantamine study to date 
found increased Glu/tCr in the right hippocampus that correlated with MMSE scores (38) and 
no change in NAA/tCr ratio. In summary, NAA/tCr was increased in seven regions and 
decreased in three regions, while mI/tCr was increased in three regions and decreased in one 
region. The one study that reported changes in Glu found an increase in Glu/tCr that 
correlated with MMSE, indicating a beneficial effect in the right hippocampus following 
galantamine treatment. These studies indicate region-specific effects of ChEI treatment. 
However it is also possible that the discrepancies in the reported ratio changes may be due to 
any combination of differences in cohorts, field strengths, duration of treatment, and spectral 
quantification methodology. Interestingly, a previous study performed by our group to 
examine the effect of four months of donepezil treatment also found that NAA/tCr decreased 
by 16% in the right hippocampus in subjects with AD after four months of treatment (32). 
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The large decrease in NAA/tCr found in the current study cannot be explained by atrophy 
since the effect of tissue partial volume within the voxel was eliminated by taking the ratio of 
metabolite levels to tCr. Also, it should be noted that test-retest reliability measurements of 
NAA/Cr made in a group of young healthy controls using the same methodology as that 
described in the current manuscript demonstrate no changes over a period of six months (p > 
0.7, data not shown). An increase in the absolute level of tCr could contribute to the large 
observed decrease in NAA/tCr. However, in a previous study by our group the 16% decrease 
in NAA/tCr over 4 months in AD subjects receiving donepezil treatment (32) was attributed 
to a 13% decrease in NAA while a significant increase in tCr was not observed. Similarly, in 
the current study there was neither a significant decrease in absolute NAA or a significant 
increase in absolute tCr (Figure 3.4). 
The one other 1H MRS rivastigmine study to date found increased NAA/tCr in the 
frontal cortex and increased mI/tCr in the occipital cortex after four months of treatment (37), 
while the current study found a decrease in NAA/tCr in the bilateral posterior cingulate 
cortex, indicating a differential effect of brain region. Furthermore, a previous study that 
reported changes in bilateral posterior cingulate found an increase in NAA/tCr following 
donepezil treatment, indicating a differential effect between donepezil and rivastigmine 
treatment. 
 Previous 1H MRS studies of subjects with AD that are not receiving treatment or that 
are stable on treatment have reported decreased NAA or NAA/tCr compared to control 
subjects (40-46,54) including in the posterior cingulate cortex (46,54). These studies are 
summarized in Table 3.3, for comparison to the current treatment study. 
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Table 3.3: Summary of previously reported longitudinal NAA findings in AD 
 
Study  % on N Interval Location  NAA findings  Interpolated  
  ChEI*           NAA change 
             over 4 months 
 
Schott  71 42 24 months Midline PC  NAA/tCr decreased  -0.73% 
et al., 2010        by 2.2% per year 
 
Kantarci 75 60 13 months Bilateral PC  NAA/tCr decreased  -0.55% 
et al., 2007     gyri   by 1.8% over 13 months 
 
Dixon  NR 9 12 months Left and right  No longitudinal change N.C. 
et al., 2002     hippocampus 
 
Jessen  NR 13 23 months Medial temporal No longitudinal change N.C. 
et al., 2001     lobe   NAA/tCr correlated 
         with MMSE 
 
Adalsteinsson NR 12 12 months Averaged grey NAA decreased  -4.1% 
et al., 2000     matter   by 12.4% over 1 year 
               
                 ____________________________ 
               
           average = -1.8%  
 
 
* - percent of subjects on cholinesterase inhibitor treatment at baseline 
N - number of participants, PC - posterior cingulate, NR - not reported, 
N.C. - no change over time 
 
The three previous studies that reported longitudinal changes in NAA/tCr all reported 
decreases over time (42,72,73), with an interpolated average 1.8% decline in NAA/tCr over 
four months. The 12.7% decrease in NAA/tCr over four months observed in the current study 
is greater than expected based on these previous studies. However, it is important to note that 
we measured the short-term effects of treatment, as all subjects were treatment naïve at the 
baseline measurement and were then treated for 4 months. Conversely, most subjects in the 
studies summarized in Table 3.3 were either stable on treatment or untreated and the time 
between measurements was typically 12-24 months. Therefore, short-term changes due to 
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treatment would not be detected. 
It is worth noting that the decrease in NAA/tCr found in the current study could not 
be attributed to a significant decline in absolute NAA or a significant increase in absolute tCr 
and therefore provides an example of the potential increase in sensitivity of metabolic ratios. 
Both NAA/tCr and Glx/tCr were positively correlated with the MMSE score. This result 
indicates that maintained or improved cognitive performance is associated with preserved 
neuronal function. It is not possible to determine whether this effect is due to rivastigmine 
treatment or disease progression but regardless suggests that the NAA/tCr ratio is an 
objective measure of cognitive function following symptomatic drug treatment. 
 The limitations of this study include the small sample size (fourteen subjects) and the 
acquisition of 1H MRS data from only one brain region. Future studies would benefit from 
investigating multiple regions that are involved in progressive AD, as well as control regions. 
However the posterior cingulate cortex region used in the current study should be considered 
for future multi-site studies as the region is implicated in the progression of Alzheimer’s 
disease and allows high quality reproducible metabolite level measurements. Follow-up with 
longer treatment duration may also provide additional insight into whether rivastigmine 
treatment maintains NAA/tCr and Glx/tCr levels and cognition. 
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Chapter 4 
 
Semi-LASER 1H MR spectroscopy at 7 Tesla in human 
brain: metabolite quantification incorporating subject-
specific macromolecule removal 
 
 A version of this chapter has been previously published. Penner J and Bartha R. Semi-
LASER 1H MR spectroscopy at 7 Tesla in human brain: Metabolite quantification 
incorporating subject-specific macromolecule removal. Magn Reson Med 2014; Epub ahead 
of print. doi: 10.1002/mrm.25380.. 
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4.1  Introduction 
 Proton (1H) magnetic resonance spectroscopy (MRS) has been used extensively to 
detect metabolite levels in vivo in various neuropathological conditions in the brain (1-6). 
Most clinical studies use long echo times (TE > 100 ms) to detect changes in N-
acetylaspartate (NAA), total creatine (tCr = Cr + PCr), and choline (Cho = GPC + PC). 
Long-TE spectra (e.g. TE = 135 ms, 270 ms) are relatively simple to analyze as they contain 
easily resolved peaks from NAA, tCr, and Cho and few overlapping signals from 
macromolecules (7). In contrast, acquisition with short-TE (TE < 50 ms) reduces signal loss 
from J-coupling phase modulation producing visible multiplets from metabolites including 
glutamate (Glu), glutamine (Gln), and myo-inosital (mI). However, quantification of all 
metabolites becomes more difficult due to overlapping macromolecule signals (7) that must 
be resolved. 
 The in vivo spectrum can be fitted using linear combinations of known metabolite 
lineshapes (8). This approach has been successfully demonstrated by several groups at field 
strengths ranging from 1.5T to 9.4T (8-16). However, the method is only accurate when all 
contributions to the in vivo spectrum are incorporated during fitting (12), including 
macromolecule resonances that extend beneath the 2-4 ppm metabolite region and overlap 
with metabolites (e.g. NAA, Glu, Gln, and tCr). One approach to account for the 
macromolecule contribution is to include prior information about the macromolecule 
lineshapes in the fitting (17). However, this becomes difficult as macromolecule 
contributions to the spectrum have been shown to change in disease conditions including 
ischemic stroke (18) and cancer (19,20) as mobile lipids become MR visible, potentially 
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leading to inaccurate metabolite measurements (21). Furthermore, Opstad et. al. (19) showed 
that the macromolecule signals differ substantially between tumor types. 
 Alternatively, a subject-specific macromolecule spectrum can be acquired in addition 
to the metabolite spectrum, and subsequently subtracted from the metabolite spectrum to 
remove the macromolecule contributions (21). Although this approach increases acquisition 
time and reduces signal to noise ratio due to the subtraction of one spectrum from the other 
(21), it provides the most direct and accurate method to identify subject specific 
macromolecule contributions. The longitudinal relaxation times (T1) of macromolecules are 
generally shorter (T1 ~ 430 ms at 7T (22)) than metabolites (T1 ~ 1600 ms at 7T (22)), 
allowing for the direct measurement of the macromolecule spectrum by inversion-nulling the 
metabolite signals (23,24). However, the inversion-nulling scheme must be optimized for a 
given field strength because the T1 time constants of the metabolites are field strength 
dependent. 
 Signals arising from outside the volume of interest must also be minimized. For 
example, outer volume saturation (OVS) can be used to reduce signals from outside of the 
measurement volume that may contaminate the spectrum. However, spoiling of unwanted 
signals from outside of the measurement volume is often not sufficient to eliminate lipid 
contamination in single-volume stimulated-echo acquisition mode (STEAM) spectroscopy 
(24). Furthermore, OVS can decrease the SNR of metabolites within the measurement 
volume due to magnetization transfer effects (25). Alternatively, the use of localization by 
adiabatic selective refocusing (LASER) decreases the need for OVS due to the excellent 
slice-selection profiles obtained when using pairs of adiabatic full passage (AFP) pulses (26); 
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a significant advantage for high field applications.   
 The use of ultra-high magnetic field strength (e.g. !7T) produces 1H MRS spectra with 
greater signal-to-noise ratio (SNR) and improved spectral resolution (15,27-32), generally 
improving overall metabolite quantification. However, power deposition also increases due 
to the increase in resonance frequency, and B0 and B1+ (RF transmit field) magnetic field 
homogeneity is difficult to achieve. These factors must all be considered when designing the 
optimal spectroscopy protocol. Spectra can be acquired with a semi-LASER sequence (33-
35), rather than the LASER pulse sequence, to significantly reduce power deposition (33-35). 
Furthermore, B0 homogeneity can be optimized with an automated shimming technique such 
as RASTAMAP (36), and B1+ can be optimized using a parallel transmission shimming 
protocol (37) that maximizes excitation efficiency based on B1+ amplitude and uniformity 
while minimizing the specific absorption rate (SAR). 
 The purpose of this study was to develop an in vivo 1H short-TE MRS protocol at 7T to 
reliably quantify absolute metabolite concentrations in the brain. This goal was achieved 
incorporating parallel transmit excitation, subject-specific macromolecule removal, and 
tissue partial volume measurements. 
 
4.2  Methods 
4.2.1 General MRS protocol 
 An Agilent 7 Tesla head-only MRI scanner (Agilent Inc, Walnut Creek, CA) with a 
Siemens AC84 7T gradient coil (Siemens, Erlangen, Germany) was used to acquire all 
imaging and spectroscopic data. At the time of data collection the system had sixteen 
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controllers driving sixteen radiofrequency (RF) transmit/receive channels. Prior to the 
acquisition of imaging data, linear and higher-order shims were used to optimize the static 
magnetic field (B0) over the entire head (global) using an automated shimming sequence 
(RASTAMAP) (36). After the imaging data were acquired, RASTAMAP was used again to 
maximize B0 homogeneity within the MRS voxel. Following the initial global B0 shim and 
before images were acquired, B1+ maps were produced for each of the 16 transmitters. These 
maps were then used to optimize the overall B1+ power and uniformity, while minimizing 
SAR, with a slice-by-slice parallel transmit shimming protocol (37) that modulated the 
driving amplitudes and phases of the separate transmit elements. This process occurred over 
the entire head prior to imaging, and again over the voxel prior to MRS data collection (37). 
 MRS data were acquired with a semi-LASER (33-35) sequence that is based on the 
original LASER sequence (26) but with a single slice-selective 90° excitation pulse used in 
place of the original non-selective 90° excitation pulse and the first pair of 180° adiabatic full 
passage (AFP) refocusing pulses. A 2 ms slice-selective sinc pulse was used for excitation 
and 3.4 ms hyperbolic secant AFP (HS2 R10, 3.2 kHz bandwidth) pulses were used for 
selective-refocusing in the remaining two orthogonal planes. The pulse power levels were 
manually calibrated to ensure pulses were optimized. The optimal adiabatic pulse power was 
determined by acquiring a water unsuppressed spectrum repeatedly while increasing the RF 
power until the amplitude of the water spectrum reached and maintained a maximum value. 
The power corresponding to the first instance of the maximum signal intensity was identified 
and this value plus 1 dB was used in the data acquisition to ensure the adiabatic condition 
was satisfied. The semi-LASER sequence was used as it offers a shorter echo-time (TE) and 
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lower RF power deposition than the original LASER sequence because of the removal of one 
pair of refocusing pulses. The water signal was suppressed with variable pulse power and 
optimized relaxation delays (VAPOR) water suppression (17) with one additional pulse after 
the seventh VAPOR pulse, adjusted to yield optimal in vivo water suppression. The 
macromolecule spectra were acquired by nulling the metabolite signals; this was achieved 
using a double-inversion nulling method (38) that utilized two AFP (HS2 R10, 5 ms, 2.2 kHz 
bandwidth) pulses. Double-inversion was used because one inversion pulse can only fully 
suppress signals that relax with one specific T1 value. At 7T the T1s of metabolites in the 
brain range from 1.1-2.1s (22). Therefore, the use of the double inversion-nulling improves 
the nulling efficiency of metabolites with a range of T1 time constants. 
 The 16-channel transmit/receive phased-array radiofrequency (RF) coil used to acquire 
the MRS data produced sixteen spectra per acquisition. These spectra were combined using 
an in-house script written in Matlab (The Mathworks Inc., Natick, MA) as described in 
Brown et. al. (39), to produce a single spectrum per acquisition. The method used a coil 
sensitivity weighting factor (wn) computed from the noise in each channel, a coil proximity 
weighting factor (an) determined from the maximum amplitude of the signal from each 
channel, and a phase compensation factor (!n) to align the phases in all sixteen channels. 
 Lineshape distortions that arise from magnetic field inhomogeneities and induced eddy 
currents and lead to errors in spectral peak area estimations were corrected with 
QUAntification improvement by converting LIneshapes to the lorentzian TYpe (QUALITY) 
deconvolution (40) performed on the initial 200 complex time domain data points (50 ms) 
followed by eddy current correction (ECC) (41) on the remaining 1800 data points (450 ms). 
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This combined QUALITY/ECC post-processing (QUECC,(27)) uses the unsuppressed water 
time domain data as the reference signal to correct the metabolite data. The QUECC junction 
was set to 50 ms. All residual water in the spectrum was also removed prior to fitting the 
metabolite signals. Water was removed by subtracting all resonances found between 4.2 and 
6.2 ppm (water at 4.7 ppm) following an automated Hankel singular value decomposition 
(HSVD) fit (512 points) of the data (9,10,42,43). 
 The processed metabolite spectra were fitted in the time domain using the fitMAN 
software (9,10). Specifically, a Levenberg-Marquardt minimization routine (44) was used 
that incorporated prior knowledge from sixteen metabolite lineshapes including: N-
acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), "-aminobutyric acid (GABA), 
aspartate (Asp), creatine (Cr), glucose (Glc), glutamate (Glu), glutamine (Gln), glutathione 
(Glth), glycerophosphorylcholine (GPC), myo-inositol (mI), phosphocreatine (PCr), 
phosphorylcholine (PC), phosphorylethanolamine (PEth), scyllo-inositol (Scy), and taurine 
(Tau). All metabolites were purchased from Sigma-Aldrich Canada Co. (Oakville, Ontario). 
Alanine and lactate were excluded from the current study as they could not be fit reliably. 
Prior knowledge regarding the lineshape of each metabolite was obtained as previously 
described (10), using the identical semi-LASER pulse sequence used to acquire all in vivo 
data. More specifically, high-resolution in vitro spectra (11,14) were acquired from aqueous 
solutions of each metabolite (100 mM each, except NAAG which had a concentration of 5.1 
mM due to the cost of NAAG, all pH adjusted to 7.04). Each solution contained sodium 3-
trimethylsilyl-propionic acid (TSP) as a chemical shift and Lorentzian damping reference 
(10). The chemical shift and Lorentzian damping of each resonance within each metabolite 
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was calculated relative to the TSP resonance to eliminate B0 and magnetic field homogeneity 
dependencies in the fitting template. The chemical shifts and Lorentzian dampings of all 
metabolites were each fixed to a common parameter and the resonance amplitudes for a 
given metabolite were fixed to a relative amplitude parameter, so that the relative amplitude 
of each metabolite was free to be adjusted during the fitting process (10). 
 
4.2.2 Optimal inversion times for metabolite suppression 
 Accurate measurement of the macromolecule baseline in each subject required 
suppression of metabolite signals. This suppression was achieved with a double inversion 
nulling method (38) that used two AFP inversion pulses (5 ms, HS2 R10, 2.2 kHz 
bandwidth) at inversion times TI1 (time between the first inversion pulse and the 90° 
excitation pulse in the semi-LASER sequence), and TI2 (time between the second inversion 
pulse and the 90° excitation pulse in the semi-LASER sequence). To determine the optimal 
inversion times (TI1 and TI2) for metabolite suppression, the longitudinal relaxation times 
(T1) of NAA, Glu, tCr, and Cho were measured from a 3x3x3 cm3 voxel in the parietal-
occipital region (Figure 4.1) of seven healthy volunteers (27.1 ± 2.4 years) using a research 
protocol approved by with the University of Western Ontario Health Sciences Research 
Ethics Board. 
 The semi-LASER sequence was preceded by a single AFP inversion pulse (5 ms, HS2 
R10, 2.2 kHz bandwidth), and a water suppressed spectrum was acquired at as many of the 
following inversion times (TI) as time allowed in each subject: 140, 240, 340, 640, 1140, 
2140, 2640, 3140, 3840, 4040, 4440 ms (TE/TR = 38/5000 ms, receiver bandwidth = 4 kHz, 
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voxel volume = 27 cm3, 32 averages). An unsuppressed water spectrum (TE/TR = 38/5000 
ms, receiver bandwidth = 4 kHz, voxel volume = 27 cm3, 8 averages) was also acquired in 
each subject and used as a reference for QUECC correction (50 ms QUECC junction). 
 
 
Figure 4.1: Axial T2-weighted 2D FLASH image (TR/TE = 1000/6.5 ms, 1x1x2 mm3) with 
the 3x3x3 cm3 voxel (white square) used to determine the optimal inversion times for 
metabolite suppression and the 2x2x2 cm3 voxel (dashed white square) used to determine the 
in vivo metabolite concentrations, both in the parietal-occipital region. 
 
To reduce the influence of the broad (short T2) macromolecule signals on the measurement of 
metabolite T1, a set number of data points were omitted from the beginning of each time-
domain data set when fitting in the time domain. It was empirically determined that 14 points  
(0.0035s) provided the best compromise between maintaining spectral signal to noise ratio 
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and removing macromolecules signals that contaminated the measured metabolite areas. For 
the measurement of T1, the amplitude of the tCrCH3 and ChoCH3 peaks were fit independently 
from the other peaks in the metabolite spectrum. Using this approach, inversion recovery 
curves were produced for NAA, Glu, tCr (CH3 at 3.03 ppm), and Cho (CH3 at 3.19 ppm) by 
plotting their fit contributions, Mz(t), at each inversion time (TI), and then the data were 
fitted to an exponential regrowth equation (Equation 4.1) using Prism (GraphPad Software, 
Inc., Version 6.0c, La Jolla, CA) (Figure 4.2); 
 
M z(TI ) = M 0 1! e
!TI /T1 ! ae!TI /T1 + ae!TR /T1( )             (4.1) 
 
where M0 is the steady-state metabolite signal and a is the inversion fraction following 
imperfect inversion, such that Mz(0) = -aM0(1 - exp(-TR/T1)). The fit directly yielded the 
longitudinal relaxation time constants (T1) listed in Table 4.1. 
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Figure 4.2: The inversion recovery curves for NAA, Glu, tCrCH3, and ChoCH3. Each curve 
was fitted to the single inversion recovery equation (Equation 4.1 - black lines) to solve for 
the T1 time constant. 
 
 
 
 126 
Table 4.1: T1 and T2 time constants used to calculate metabolite mM concentrations 
 
    T1 (s)   Reference  T2 (ms) Reference 
 
Tissue Water  1.70   (45)   52.5  (46) 
CSF Water   4.43   (47)   141  (46) 
NAA    1.71 ± 0.15  Current study 341  (48) 
NAAG   1.21   (22)   274  Avg 
Glu/Gln   1.68 ± 0.19  Current study 274  Avg 
Cr/PCr (3.03 ppm) 1.63 ± 0.10  Current study 221  (48) 
Cr/PCr (3.92 ppm) 1.13   (22)   221  (48) 
PC/GPC (3.19 ppm) 1.41 ± 0.09  Current study 260  (48) 
Glth    1.14   (22)   274  Avg 
mI    1.28   (22)   274  Avg 
PEth    1.31   (22)   274  Avg 
Scy    1.31   (22)   274  Avg 
Tau    2.15   (22)   274  Avg 
Other    1.61   Avg   274  Avg 
 
Avg - Relaxation time was set as the average of NAA, Glu, tCr (3.03 ppm), and Cho. 
T1s from the current study listed with ± standard error of the fit. 
 
 
The signal equation following double inversion (Equation 4.2) was then used to model Mz as 
a function of TI1 and TI2 for each metabolite (NAA, Glu, tCr, and Cho). 
 
Mz (TI1,TI2 ) =M0 1! 2e!TI2 /T1 + 2e!TI1/T1 ! e!TR/T1( )       (4.2) 
 
To suppress a metabolite signal Mz(TI1,TI2) was set to zero in Equation 4.2, and then 
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rearranged to give Equation 4.3. 
 
TI2 = !T1 ln
1
2 + e
!TI1/T1 !
1
2 e
!TR/T1"
#
$
%
&
'             (4.3) 
 
The T1 values for NAA, Glu, tCr, and Cho were each substituted into Equation 4.3, 
producing four equations of TI2 versus TI1 that are plotted in Figure 4.3. Each one of these 
curves defines the TI1 and TI2 values that will null that respective metabolite. 
 
 
Figure 4.3: TI1 versus TI2 curves for NAA, Glu, tCrCH3, and ChoCH3. Each of these curves 
defines TI1 and TI2 values that will null that respective metabolite. A single set of TI1 and TI2 
values at the point closest to the intersection of all four curves (see zoomed overlay), results 
in optimal simultaneous suppression of all four metabolites. 
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4.2.3 Average metabolite concentrations in healthy brain 
 Five healthy volunteers (28.0 ± 2.7 years) were scanned using a research protocol 
approved by the University of Western Ontario Health Sciences Research Ethics Board. To 
begin each scan session: 3 localizer images were acquired, an automated global B0 shim (36) 
was performed, and B1+ (transmit magnetic field) maps were acquired for subsequent B1+ 
shimming (37). T2-weighted 2D FLASH (Fast Low Angle SHot) images (Figure 4.1) were 
acquired (TE = 5.5 ms, TR = 1000 ms, flip angle = 30°, 1x1 mm2 in-plane resolution, slice 
thickness = 2 mm, scan time = 3 minutes) for planning the MRS voxel: a 2x2x2 cm3 volume 
positioned in the bilateral parietal-occipital cortex (Figure 4.1) in each participant. In 
preparation for MRS data acquisition the B1+ field was optimized over the MRS voxel using 
the acquired B1+ maps (37), and an automated local B0 shim was performed (36). MRS data 
were acquired in a similar manner as described previously (21). First, eight water spectra (no 
water suppression or metabolite nulling) were acquired (TE/TR = 38/3700 ms, receiver 
bandwidth = 4 kHz, voxel volume = 8 cm3) and summed to provide a measure of the total 
water signal in the voxel. Then, 128 water suppressed full spectra (Figure 4.4a - TE/TR = 
38/3700 ms, receiver bandwidth = 4 kHz, voxel volume = 8 cm3) and 128 water suppressed 
macromolecule spectra (Figure 4.4b - TE/TR = 38/3700 ms, receiver bandwidth = 4 kHz, 
voxel volume = 8 cm3, TI1/TI2 = 3.14/0.70s) (metabolite-nulled) were collected in an 
interleaved manner to minimize subtraction errors due to motion during the acquisition. 
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Figure 4.4: (a) Representative water suppressed semi-LASER spectrum (TE/TR = 38/3700 
ms, 2x2x2 cm3 volume), (b) macromolecule spectrum, (c) HSVD fit of macromolecule 
spectrum, and (d) resulting metabolite spectrum following macromolecule removal, from one 
participant (1 Hz exponential filter applied to all spectra shown). 
 
Finally, the transverse decay of the water signal (Figure 4.5) was measured by acquiring 
water spectra (TR = 5s, receiver bandwidth = 4 kHz, voxel volume = 8 cm3) at different TEs 
ranging from 38 ms up to 2000 ms. These data were used to calculate the amount of cerebral 
spinal fluid (CSF) water within the MRS voxel (49-51). 
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Figure 4.5: Representative plot of water signal (normalized to the signal at the shortest echo 
time) versus echo time (TE), with superimposed two-component exponential decay fit. The 
individual contributions from CSF and tissue are shown, illustrating their unique initial 
amplitudes and decay rates. 
 
 The macromolecule spectrum was fitted (Figure 4.4c) using a Hankel singular value 
decomposition (HSVD, 250 points, 25-35 peaks) (42,52). Although using this fitted curve for 
subtraction removes the appearance of random noise from the macromolecule spectrum, the 
underlying uncertainty and error propagates to the metabolite spectrum and decreases the 
effective signal to noise of this measurement. Since the macromolecule signals are also 
partially saturated following the inversion pulses designed to null the metabolite signals, the 
macromolecule spectrum needed to be scaled prior to subtraction (21) from the full spectrum. 
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The saturation of the macromolecule signal was calculated (using Equation 4.2, T1,MM = 430 
ms , TI1 = 3.14s, and TI2 = 0.70s) at the time of the acquisition of the full spectrum and then 
again at the time of the acquisition of the macromolecule spectrum, yielding the 
macromolecule spectrum scaling factor, 1.64. T1MM is the longitudinal relaxation time of the 
macromolecule signals in the 0.5 - 1.8 ppm range (22). Following scaling, the 
macromolecule contribution was subtracted from the full spectrum (42,52), yielding the 
metabolite spectrum (Figure 4.4d). 
 Prior to fitting the metabolite signals, any remaining unsuppressed water signal was 
removed by performing a HSVD fit (512 points, auto detected number of peaks) and 
removing all resonances between 4.2 and 6.2 ppm (Figure 4.6a, water at 4.7 ppm) 
(9,10,42,43). Fitted metabolite levels were corrected to account for the residual metabolite 
signal present in the macromolecule spectrum due to incomplete nulling. The contribution of 
the metabolite to the macromolecule spectrum was estimated using the known metabolite T1 
value and the TI1 and TI2 values used in the acquisition of the metabolite-nulled spectrum. 
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Figure 4.6: Representative (a) metabolite spectrum with superimposed fit and (b) the residual 
difference between the data and fit, from one participant (1 Hz exponential filter applied to 
the data and the residual). The individual components are shown below the spectrum: (c) 
NAA, (d) Glu, (e) Gln, (f) GABA, (g) Glth, (h) Asp, (i) Cr, (j) PCr, (k) PC, (l) GPC, (m) Tau, 
(n) PEth, (o) sI, (p) Glc, and (q) mI. 
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Metabolite levels were then normalized to the amount of unsuppressed water in each MRS 
data set and then corrected for T1 and T2 relaxation using values determined in this study and 
from the literature (Table 4.1). The fractional water content was taken as 78%, the average of 
gray matter and white matter (14). The cerebral spinal fluid (CSF) and tissue (gray matter 
and white matter) fractions were determined for each 1H MRS measurement by fitting the 
unsuppressed water signal as a function of echo time (TE) to the following bi-exponential 
decay equation (51); 
 
S(TE) = ACSFe
!TE /T2 ,CSF + Atissuee
!TE /T2 ,tis su e
         (4.4) 
 
where ACSF and Atissue are the initial amplitudes of the CSF and tissue signals, respectively.  
Fitting was performed using Prism (GraphPad Software, Inc., Version 6.0c, La Jolla, CA). 
This approach exploits the longer transverse relaxation time constant (T2 ~ 150 ms) of CSF 
water compared to tissue (T2 ~ 50 ms) (46) to separate the water decay signal into CSF and 
tissue components (49-51). Figure 4.5 shows the result of the two-component exponential 
decay fit in one representative water decay data set. 
 
4.3  Results 
4.3.1 Optimal inversion times for metabolite suppression 
 Water-suppressed spectra with a range of single inversion times were successfully 
acquired from a 3x3x3 cm3 voxel in the parietal-occipital region (Figure 4.1) of all seven 
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volunteers. The NAA, Glu, tCrCH3, and ChoCH3 peak areas were measured as a function of 
inversion time (Figure 4.2) and were fitted to the inversion recovery equation (Equation 4.1) 
to solve for the T1 time constants. The measured T1 time constants for NAA, Glu, tCrCH3, and 
ChoCH3 are listed in Table 4.1, along with the T1 time constant values of other metabolites 
taken from the literature. Metabolite T1 time constant values range from ~1.1-2.1s and 
therefore a single inversion pulse will not null all metabolites simultaneously. To increase 
nulling efficiency, a double inversion pulse was used to suppress metabolite signals. 
 To determine the optimal inversion times for the double-inversion nulling scheme, the 
T1 time constants of NAA, Glu, tCrCH3, and ChoCH3 were each substituted into the double-
inversion recovery equation (Equation 4.3) and Mz(TI1,TI2) was set equal to zero. This 
approach yielded four equations that defined the corresponding TI1 and TI2 values that would 
null a particular metabolite. All four equations were plotted on the same graph (Figure 4.3) 
and the TI1 and TI2 values that produce optimal simultaneous suppression of all four 
metabolites were read directly from the plot. These values corresponded to TI1 = 2.09s and 
TI2 = 0.52s. 
 
4.3.2 Average metabolite concentrations in healthy brain 
 Figure 4.1 also shows the positioning of the 2x2x2 cm3 1H MRS voxel in the parietal-
occipital region of one volunteer. Water-unsuppressed, water-suppressed metabolite, and 
water-suppressed macromolecule spectra were successfully acquired in all volunteers. The 
average SNR for the acquired spectra, calculated as the NAA peak intensity over the standard 
deviation of the baseline, was 48 ± 6. Using the multi-echo transverse decay of the tissue 
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water signal, two components were successfully identified in each voxel attributed to CSF 
(long component) and tissue (short component). The average CSF and tissue fractions within 
the measurement volumes were 8.2 ± 2.0% and 91.8 ± 2.0%, respectively. The 
macromolecule removal process is demonstrated in one volunteer in Figure 4.4. Figure 4.6 
shows a spectrum from one volunteer with: the fit result superimposed onto the data, the 
residual difference between the data and the fit shown below, and the individual metabolite 
components shown underneath. Table 4.2 lists the group average and standard deviation of 
metabolite concentrations in units of mM, as well as the Cramér-Rao lower bounds (53) on 
quantification precision. The percent coefficient of variation (%CV) was less than 10% for 
NAA, tCr, Cho, and mI, and less than 20% for Glu and Gln. 
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Table 4.2: Average metabolite concentrations 
 
Metabolite  Average concentration  Average Cramér-Rao SD 
   ± SD (mM) 
 
NAA   11.8 ± 0.8    0.10 
Glu   10.7 ± 1.6    0.15 
Gln   2.2 ± 0.4    0.33 
GABA  n.d.     n.d. 
Asp   3.8 ± 1.3    0.08 
NAAG  n.d.     n.d. 
Tau   1.0 ± 0.5    0.09 
Glc   1.2 ± 0.2    0.07 
PEth   1.2 ± 0.5    0.08 
Cr   4.1 ± 0.6    0.36 
PCr   3.5 ± 0.9    0.22 
mI   5.9 ± 0.3    0.05 
Glth   1.6 ± 0.3    0.03 
Scy   0.4 ± 0.1    0.04 
PC   0.3 ± 0.1    0.04 
GPC   1.5 ± 0.4    0.05 
 
SD - standard deviation, n.d. - not detected 
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4.4  Discussion 
 The initial goal of this work was to determine the optimal inversion times that would 
produce a short echo-time metabolite-nulled macromolecule spectrum for a semi-LASER 
pulse sequence at 7 Tesla. To this end we measured the in vivo T1 relaxation time constants at 
7T for NAA, Glu, tCrCH3, and ChoCH3, which were then used to calculate the inversion times 
that would maximize metabolite suppression. Subsequently, a subject-specific 
macromolecule spectrum was acquired alongside each metabolite spectrum using a short-TE 
single voxel semi-LASER protocol. Following removal of the macromolecule component of 
the spectrum, the metabolite contributions were fitted with a linear combination of prior 
knowledge metabolite templates. Using this approach for MRS data collected from the 
parietal-occipital region of young healthy controls and combining with corrections for tissue 
partial volume and relaxation, absolute metabolite concentrations were determined by 
referencing to the unsuppressed water signal within the voxel. Metabolite T1 values (Table 
4.1) measured in the current study were consistent with a previous study that also measured 
in vivo T1 values of metabolites at 7T (22). These values are slightly higher than the T1 
values measured at lower field strengths (54,55). Metabolite concentrations were also 
consistent with previous measures made in a number of different brain regions (Table 4.3). 
 The semi-LASER (33-35) MRS sequence used for volume selection in the current 
study, utilized a 90° sinc pulse for slice selection, and 2 pairs of AFP pulses to refocus the 
signal in the remaining two orthogonal planes. Adiabatic pulses have excellent slice-selection 
profiles (26) compared to conventional pulses used in STEAM and PRESS, reducing 
contamination from outside of the measurement volume. Therefore unlike in the cases of 
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STEAM and PRESS, OVS was not required in the current study. The semi-LASER sequence 
was used instead of the conventional LASER sequence (26) to reduce the number of high-
power AFP pulses from 6 to 4, resulting in lower power deposition and a shorter minimum 
TE. 
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Table 4.3: Reported metabolite concentrations measured with 7T single-voxel 1H MRS 
 
Study  N  Sequence Brain  SNR  NAA Glu Gln tCr Cho mI 
[Ref]  [Age]  [TE]  region  [NT] 
[year]  [Volume] 
Current 5  semi-LASER POC  48±6 Mean* 11.8 10.7 2.2 7.6 1.8 5.9 
study  28±3  38 ms    128 St.D. 0.8 1.6 0.4 0.4 0.2 0.3 
  8 mL       %CV 6.7 15 20 5.9 8.5 5.4 
 
Wijten. 4  STEAM AC  47.5 Mean! 12.8 15.5 3.7 9.1 2.3 6.4 
(32)  24±2  14 ms    32 St.D. 1.2 0.4 0.6 0.7 0.2 0.8 
2013  27 mL       %CV 9.4 2.6 16 7.7 8.7 13 
 
      DLPFC 46 Mean! 10.5 10.1 2.3 6.5 1.4 4.7 
        32 St.D. 1.0 1.2 0.8 0.6 0.2 0.9 
         %CV 10 12 35 9.2 14 19 
 
Steph.  12  STEAM ACC  63±10 Mean! 6.3 11.0 2.3 6.1 1.6 3.8 
(30)  28±11  16 ms    288 St.D. 0.7 1.4 0.4 0.6 0.2 0.3 
2011  9 mL       %CV 11 13 17 10 13 7.9 
 
  8.6 mL   Insula  36±11 Mean! 7.1 12.1 2.5 6.5 1.7 3.8
        288 St.D. 0.6 1.3 0.5 0.4 0.2 0.5 
         %CV 8.5 11 20 6.2 12 13 
 
Mekle  6  SPECIAL OC  77±5 Mean* 11.8 9.9 2.2 8.0 1.1 5.7 
(15)  22-26  6 ms    64 St.D. 0.2 0.9 0.4 0.4 0.05 0.5 
2009  8 mL       %CV 1.7 9.1 18 5.0 4.5 8.8 
 
Tkac  10  STEAM OC  194±27Mean*12.1 9.6 2.8 8.4 1.2 6.3 
(31)  24±5  6 ms    160 St.D. 0.7 0.6 0.4 0.6 0.1 0.6 
2009  8 mL       %CV 5.8 6.3 14 7.1 8.3 10 
N - number of participants, NT - number of averages, semi-LASER - semi-localization by 
adiabatic selective refocusing, POC - parietal-occipital cortex, %CV - percent coefficient of 
variance, STEAM - stimulated echo acquisition mode, AC - anterior cingulate, DLPFC - 
dorsolateral prefrontal cortex, ACC - anterior cingulate cortex, SPECIAL - spin-echo full-
intensity acquired localized, OC - occipital cortex 
* - mM concentration 
! - institutional units of concentration 
%CVs from previous studies were calculated from the reported mean and standard deviations 
- (St. Dev/Mean) X 100, and mean and standard deviations for Tkac et. al., 2009 were read 
from bar graphs as they were not listed explicitly. 
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The macromolecule contribution to the short-TE spectrum was measured for each participant. 
Although this approach adds ~8 min/scan, it ensures that the macromolecule signals in each 
spectrum are accurately represented rather than approximated using a generalized 
macromolecule lineshape in the prior knowledge template. Furthermore, the full and 
macromolecule spectra were acquired in an interleaved fashion (21) to minimize subtraction 
errors due to subject movement during the scan (~16 min to acquire the full and 
macromolecule spectra). The macromolecule spectrum was acquired by nulling the 
metabolite signals using a double-inversion preparation (38), as macromolecules and 
metabolites have largely different T1’s (~430 ms for macromolecules and ~1600 ms for 
metabolites at 7T) (22). The inversion times used to acquire the macromolecule spectrum 
depend on the T1 time constants of the metabolites that are to be nulled. However effective 
nulling can be achieved across a large range of inversion times as shown in Figure 4.3. In the 
current study, the macromolecule spectra were acquired with TI1/TI2 = 3.14/.070s, which was 
somewhat different than the predicted optimal TI1/TI2 = 2.09/0.52s. However using these 
inversion times the macromolecule signals were effectively removed as demonstrated in 
Figure 4.4. The residual signals in the metabolite spectrum between 0.5 - 1.8 ppm are likely 
from macromolecule components that are not completely removed following subtraction of 
the macromolecule spectrum. The most likely reason of the incomplete removal is that the 
macromolecule T1s vary as previously shown by de Graaf et. al. (45). The residual 
metabolite signals observed in the macromolecule spectrum, most notably NAA at 2.01 ppm 
and tCr at 3.93 ppm, (Figure 4.4b and Figure 4.4c) could be reduced in future experiments by 
using TI1/TI2 = 2.09/0.52s. However, the error in metabolite levels due to residual metabolite 
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signals in the macromolecule spectrum was estimated for each metabolite by substituting the 
measured T1s (Table 4.1) along with TI1 = 3.14s and TI2 = 0.70s into Equation 4.2. The 
calculated contributions of each metabolite to the macromolecule spectrum ranged from 
0.6% to 16% of the metabolite area. This contribution was used to correct the absolute 
metabolite concentration measurements, listed in Tables 4.2 and 4.3. In a previous study by 
our group using a LASER pulse sequence at 4T with an echo time of 46 ms, the maximum 
error in metabolite levels due to residual metabolite signals in the macromolecule spectrum 
was calculated to be 6% (21). 
 The concentrations and coefficients of variance (CV) of NAA, Glu, Gln, tCr, Cho, and 
mI from this study were compared to previous 7T studies that reported metabolite 
concentrations in healthy brain (15,30-32), summarized in Table 4.3. Of note, all four of the 
previous studies at 7T used LCModel (8,56) for fitting with prior knowledge about 
metabolites and macromolecule resonances, while the current study acquired subject-specific 
macromolecule information. Also, all four of those studies corrected for water content using 
water fractions within LCModel based on T1-weighted images, while the current study 
exploited differences in the tissue and CSF water T2 relaxation times to determine the CSF 
and tissue water content within the measurement volume (51). Nonetheless, the coefficients 
of variance for the metabolite measurements in the current study were comparable to the 
previous studies. The average levels of NAA, Glu, Gln, tCr, Cho, and mI were all within ~1 
mM of the two studies that reported mM levels (15,31). Finally, the average SNR in this 
study (48 ± 6) is comparable to the average SNR in four out of five regions in the previous 
studies (ranging from 36 to 77), while one study reported an average SNR of 194 ± 27 (31). 
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These results indicate that this 7T short-TE semi-LASER 1H MRS protocol, incorporating 
subject-specific macromolecule removal, yields accurate and reproducible metabolite 
concentrations in human brain consistent with previous results. 
 Although measuring metabolite levels within the parietal-occipital cortex allowed for 
comparison with previous studies at 7T, future studies would benefit from measuring 
metabolite levels and their coefficients of variance from multiple brain regions including the 
hippocampus. Further, the measured T1 values and therefore metabolite levels could have 
been effected by the direct saturation of the water signal due to magnetization transfer effects 
between water and metabolite resonances via chemical exchange (57). Therefore metabolite 
quantification methods that do not suppress the water signal may be worth investigating in 
future studies. 
 
4.5  Conclusions 
 A short TE 1H semi-LASER spectroscopy protocol incorporating subject-specific 
macromolecule removal was developed to quantify absolute metabolite levels in the human 
brain. The optimal double inversion delay times for metabolite suppression leading to 
macromolecule detection were TI1 = 2.09s and TI2 = 0.52s. Metabolite concentrations 
measured in the parietal-occipital region of young healthy volunteers were in good agreement 
with previous studies performed in healthy brain at 7T. Measurement reproducibility was 
also similar to previous work. Incorporating subject specific macromolecule measurement 
into metabolite quantification is important in the application of short echo-time spectroscopy 
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to pathological conditions such as cancer, where macromolecule concentrations may deviate 
from the norm. 
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Chapter 5 
 
Summary and future work 
 This chapter includes a summary of the main scientific contributions, and suggests 
areas that require further investigation and development. 
 
5.1  Summary 
5.1.1 Increased glutamate in the hippocampus after galantamine 
  treatment for Alzheimer disease 
 Chapter 2 describes a study where short echo time 1H magnetic resonance spectroscopy 
at 4 Tesla was used to measure metabolite concentrations within the right hippocampus of ten 
subjects with AD following four months of galantamine treatment. The absolute glutamate 
(Glu) concentration increased, as did the ratio of Glu to total creatine (tCr) and the ratio of 
Glu to N-acetylaspartate (NAA), while the Mini-Mental State Examination (MMSE) and the 
Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog) scores did not change 
significantly. The change in the Glu/tCr ratio was positively correlated with the change in the 
MMSE scores and the change in the ratio of Glu to myo-inositol (mI) was inversely 
correlated with the change in the ADAS-cog scores, both suggesting that these metabolite 
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ratios are related to cognitive function. The increase in glutamate observed may be related to 
the action of galantamine as an allosteric potentiating ligand for presynaptic nicotinic 
acetylcholine receptors, which increases glutamatergic neurotransmission. 
 
5.1.2 Reduced N-acetylaspartate to creatine ratio in the posterior  
  cingulate correlates with cognition in Alzheimer disease following  
  four months of rivastigmine treatment 
 Chapter 3 describes a study where long echo time 1H magnetic resonance spectroscopy 
at 3 Tesla was used to measure metabolite concentrations within bilateral posterior cingulate 
cortex of fourteen subjects with AD following four months of rivastigmine treatment. The 
ratio of N-acetylaspartate (NAA) to total creatine (tCr) decreased by 12.7% following four 
months of rivastigmine treatment, while no other metabolite ratio changed and no absolute 
metabolite concentration changed. Further, neither the Mini-Mental State Examination 
(MMSE) scores or the Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog) 
scores changed. However, the change in the ratio of NAA/tCr correlated with the change in 
MMSE scores. This association between changes in NAA/tCr and cognitive performance 
suggest that NAA/tCr could be an objective indicator of response to rivastigmine, as a 
symptomatic treatment. Further, the decrease in NAA/tCr suggests continued neuronal 
impairment within the posterior cingulate in AD during rivastigmine treatment. The 
association between changes in NAA/tCr and cognitive performance suggest that NAA/tCr 
could be an objective indicator of response to rivastigmine treatment. 
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5.1.3 Semi-LASER 1H MR spectroscopy at 7 Tesla in human brain: 
  metabolite quantification incorporating subject-specific 
  macromolecule removal 
 Chapter 4 details the development of a short echo-time 1H semi-LASER spectroscopy 
protocol incorporating subject-specific macromolecule removal to quantify absolute 
metabolite levels in the human brain at 7 Tesla. Metabolite levels were measured in the 
parietal-occipital region of young healthy volunteers, where the average signal to noise ratio, 
N-acetylaspartate (NAA) peak height divided by the baseline noise standard deviation, was 
48 ± 6. The T1 time constants for NAA, glutamate (Glu), total creatine (tCr), and choline 
(Cho) were 1.71 ± 0.15s, 1.68 ± 0.19s, 1.63 ± 0.10s, and 1.41 ± 0.09s, respectively. The 
optimal double inversion delay times for metabolite suppression leading to macromolecule 
detection were TI1 = 2.09s and TI2 = 0.52s. The coefficient of variation (COV) was less than 
10% for NAA, tCr, Cho, and myo-inositol (mI), and less than 20% for Glu and glutamine 
(Gln). Metabolite concentrations and COVs were in agreement with previous studies 
performed in healthy brain at 7 Tesla, as was measurement reproducibility. Short-echo-time 
1H semi-LASER spectroscopy at 7T incorporating subject-specific macromolecule removal 
yielded reproducible brain metabolite concentrations ideal for applications in disease 
conditions where macromolecule contributions may deviate from the norm. 
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5.1.4 Conclusions 
 The first aim of this thesis work was to investigate potential metabolic biomarkers of 
Alzheimer disease (AD) that would improve diagnosis and sensitivity to subtle disease 
changes. Proton magnetic resonance spectroscopy (1H MRS) was used to measure metabolic 
changes following cholinesterase inhibitor treatment. In one 1H MRS study at 4 Tesla 
(Chapter 2), an increase in the excitatory neurotransmitter glutamate was detected in the right 
hippocampus and was associated with increased cognitive performance. In a second 1H MRS 
study at 3 Tesla (Chapter 3), the ratio of the neuronal marker N-acetylaspartate to total 
creatine was decreased in the bilateral posterior cingulate cortex, which was associated with 
cognition. The fact that both of these studies detected metabolic changes that correlated with 
cognition without significant cognitive changes may suggest that 1H MRS is more sensitive 
to changes. 
 The second aim of this thesis work was to develop a 7 Tesla 1H MRS data acquisition 
and metabolite quantification protocol to be used for future human neurological studies 
(Chapter 4). This protocol incorporates subject-specific macromolecule removal and yielded 
absolute in vivo metabolite concentrations that are in agreement with previous studies, 
making it ideal for applications in disease conditions where macromolecule contributions 
may deviate from the norm. 
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5.2  Future Work 
5.2.1 Proton MR spectroscopy of Alzheimer disease 
 Measuring metabolic fluctuations in regions of the brain that are affected in Alzheimer 
disease (AD) is logical when studying the disease, but doing so in multiple regions in the 
same study would be beneficial (i.e. in the hippocampus and posterior cingulate). This could 
allow one to determine more precisely what metabolites fluctuate in what regions, and if 
different affected regions behave similarly. It would also be beneficial to study a region of 
the brain that is not as affected by AD, such as the cerebellum, as a control region. This 
internal control could help eliminate outliers and could negate the need for a control cohort. 
However, acquiring multiple single-voxel data sets is difficult due to increased scan time, 
and therefore more patient discomfort particularly in elderly subjects. 
 Additionally, a control cohort of untreated AD patients would benefit treatment studies 
but as recommended at the Third Canadian Consensus Conference on Diagnosis and 
Treatment of Dementia (3rd CCCDTD, 2006), “provision of the best standard of care for the 
patient must always remain the priority” (1), and therefore ethics must be considered when 
denying a patient the standard AD treatment. 
 The relatively short treatment durations (four months) used in the two AD treatment 
studies could have benefited from additional follow-up measurement time-points. It would be 
interesting to know if the changes in metabolite levels detected after four months would 
continue or if they level off. It would also be interesting to know if at a later time-point the 
cognitive measures would detect differences. 
 1H MRS will remain a useful and relevant tool for neuroimaging researchers due to its 
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unique ability to non-invasively detect a number of metabolic by-products in aging and 
disease, allowing for the evaluation of medications that aim to alter brain biochemistry. 
However, improved inter-site methodological and data quality standards would allow for 
better comparison between studies and research groups. 
 
5.2.2 Proton MR spectroscopy protocol at 7 Tesla 
 Although measuring metabolite levels within the parietal-occipital cortex allowed for 
comparison with previous studies at 7 Tesla, future studies would benefit from measuring 
metabolite levels and their coefficients of variance from multiple brain regions including 
more demanding regions such as the hippocampus. Further, it would be beneficial to measure 
metabolite levels in an older population to act as a control cohort of future disease and 
treatment studies. 
 The water signal decay versus echo time fitting method served well to determine the 
voxel cerebral spinal fluid (CSF) and tissue (grey matter and white matter) fractions. 
However, it may benefit future studies to incorporate the more commonly used image 
segmentation method into the 7 Tesla 1H MRS protocol detailed in Chapter 4. This would 
allow for a more detailed grey matter, white matter, CSF voxel segmentation and potentially 
more accurate partial volume and signal relaxation corrections. 
 Lastly, metabolite quantification methods that do not suppress the water signal may be 
worth investigating to avoid possible magnetization transfer effects between water and 
metabolite resonances via chemical exchange (2). 
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DVVLJQHGRUWUDQVIHUUHGE\\RXWRDQ\RWKHUSHUVRQZLWKRXWSXEOLVKHU
VZULWWHQSHUPLVVLRQ
1R$PHQGPHQW([FHSWLQ:ULWLQJ7KLVOLFHQVHPD\QRWEHDPHQGHGH[FHSWLQDZULWLQJ
VLJQHGE\ERWKSDUWLHVRULQWKHFDVHRISXEOLVKHUE\&&&RQSXEOLVKHU
VEHKDOI
2EMHFWLRQWR&RQWUDU\7HUPV3XEOLVKHUKHUHE\REMHFWVWRDQ\WHUPVFRQWDLQHGLQDQ\
SXUFKDVHRUGHUDFNQRZOHGJPHQWFKHFNHQGRUVHPHQWRURWKHUZULWLQJSUHSDUHGE\\RXZKLFK
WHUPVDUHLQFRQVLVWHQWZLWKWKHVHWHUPVDQGFRQGLWLRQVRU&&&
V%LOOLQJDQG3D\PHQWWHUPV
DQGFRQGLWLRQV7KHVHWHUPVDQGFRQGLWLRQVWRJHWKHUZLWK&&&
V%LOOLQJDQG3D\PHQWWHUPV
DQGFRQGLWLRQVZKLFKDUHLQFRUSRUDWHGKHUHLQFRPSULVHWKHHQWLUHDJUHHPHQWEHWZHHQ\RX
DQGSXEOLVKHUDQG&&&FRQFHUQLQJWKLVOLFHQVLQJWUDQVDFWLRQ,QWKHHYHQWRIDQ\FRQIOLFW
EHWZHHQ\RXUREOLJDWLRQVHVWDEOLVKHGE\WKHVHWHUPVDQGFRQGLWLRQVDQGWKRVHHVWDEOLVKHGE\
&&&
V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQVWKHVHWHUPVDQGFRQGLWLRQVVKDOOFRQWURO
5HYRFDWLRQ(OVHYLHURU&RS\ULJKW&OHDUDQFH&HQWHUPD\GHQ\WKHSHUPLVVLRQVGHVFULEHG
LQWKLV/LFHQVHDWWKHLUVROHGLVFUHWLRQIRUDQ\UHDVRQRUQRUHDVRQZLWKDIXOOUHIXQGSD\DEOH
WR\RX1RWLFHRIVXFKGHQLDOZLOOEHPDGHXVLQJWKHFRQWDFWLQIRUPDWLRQSURYLGHGE\\RX
)DLOXUHWRUHFHLYHVXFKQRWLFHZLOOQRWDOWHURULQYDOLGDWHWKHGHQLDO,QQRHYHQWZLOO(OVHYLHU
RU&RS\ULJKW&OHDUDQFH&HQWHUEHUHVSRQVLEOHRUOLDEOHIRUDQ\FRVWVH[SHQVHVRUGDPDJH
LQFXUUHGE\\RXDVDUHVXOWRIDGHQLDORI\RXUSHUPLVVLRQUHTXHVWRWKHUWKDQDUHIXQGRIWKH
DPRXQWVSDLGE\\RXWR(OVHYLHUDQGRU&RS\ULJKW&OHDUDQFH&HQWHUIRUGHQLHGSHUPLVVLRQV
/,0,7('/,&(16(
7KHIROORZLQJWHUPVDQGFRQGLWLRQVDSSO\RQO\WRVSHFLILFOLFHQVHW\SHV
7UDQVODWLRQ7KLVSHUPLVVLRQLVJUDQWHGIRUQRQH[FOXVLYHZRUOG(QJOLVKULJKWVRQO\
XQOHVV\RXUOLFHQVHZDVJUDQWHGIRUWUDQVODWLRQULJKWV,I\RXOLFHQVHGWUDQVODWLRQULJKWV\RX
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H[FOXVLYHZRUOGULJKWVLQDOOODQJXDJHV
3RVWLQJOLFHQVHGFRQWHQWRQDQ\:HEVLWH7KHIROORZLQJWHUPVDQGFRQGLWLRQVDSSO\DV
IROORZV/LFHQVLQJPDWHULDOIURPDQ(OVHYLHUMRXUQDO$OOFRQWHQWSRVWHGWRWKHZHEVLWHPXVW
PDLQWDLQWKHFRS\ULJKWLQIRUPDWLRQOLQHRQWKHERWWRPRIHDFKLPDJH$K\SHUWH[WPXVWEH
LQFOXGHGWRWKH+RPHSDJHRIWKHMRXUQDOIURPZKLFK\RXDUHOLFHQVLQJDW
KWWSZZZVFLHQFHGLUHFWFRPVFLHQFHMRXUQDO[[[[[RUWKH(OVHYLHUKRPHSDJHIRUERRNVDW
KWWSZZZHOVHYLHUFRP&HQWUDO6WRUDJH7KLVOLFHQVHGRHVQRWLQFOXGHSHUPLVVLRQIRUD
VFDQQHGYHUVLRQRIWKHPDWHULDOWREHVWRUHGLQDFHQWUDOUHSRVLWRU\VXFKDVWKDWSURYLGHGE\
+HURQ;DQ(GX
/LFHQVLQJPDWHULDOIURPDQ(OVHYLHUERRN$K\SHUWH[WOLQNPXVWEHLQFOXGHGWRWKH(OVHYLHU
KRPHSDJHDWKWWSZZZHOVHYLHUFRP$OOFRQWHQWSRVWHGWRWKHZHEVLWHPXVWPDLQWDLQWKH
FRS\ULJKWLQIRUPDWLRQOLQHRQWKHERWWRPRIHDFKLPDJH
3RVWLQJOLFHQVHGFRQWHQWRQ(OHFWURQLFUHVHUYH,QDGGLWLRQWRWKHDERYHWKHIROORZLQJ
FODXVHVDUHDSSOLFDEOH7KHZHEVLWHPXVWEHSDVVZRUGSURWHFWHGDQGPDGHDYDLODEOHRQO\WR
ERQDILGHVWXGHQWVUHJLVWHUHGRQDUHOHYDQWFRXUVH7KLVSHUPLVVLRQLVJUDQWHGIRU\HDURQO\
<RXPD\REWDLQDQHZOLFHQVHIRUIXWXUHZHEVLWHSRVWLQJ
)RUMRXUQDODXWKRUVWKHIROORZLQJFODXVHVDUHDSSOLFDEOHLQDGGLWLRQWRWKHDERYH
3HUPLVVLRQJUDQWHGLVOLPLWHGWRWKHDXWKRUDFFHSWHGPDQXVFULSWYHUVLRQRI\RXUSDSHU
$FFHSWHG$XWKRU0DQXVFULSW$$0'HILQLWLRQ$QDFFHSWHGDXWKRUPDQXVFULSW$$0
LVWKHDXWKRU¶VYHUVLRQRIWKHPDQXVFULSWRIDQDUWLFOHWKDWKDVEHHQDFFHSWHGIRUSXEOLFDWLRQ
DQGZKLFKPD\LQFOXGHDQ\DXWKRULQFRUSRUDWHGFKDQJHVVXJJHVWHGWKURXJKWKHSURFHVVHVRI
VXEPLVVLRQSURFHVVLQJSHHUUHYLHZDQGHGLWRUDXWKRUFRPPXQLFDWLRQV$$0VGRQRWLQFOXGH
RWKHUSXEOLVKHUYDOXHDGGHGFRQWULEXWLRQVVXFKDVFRS\HGLWLQJIRUPDWWLQJWHFKQLFDO
HQKDQFHPHQWVDQGLIUHOHYDQWSDJLQDWLRQ
<RXDUHQRWDOORZHGWRGRZQORDGDQGSRVWWKHSXEOLVKHGMRXUQDODUWLFOHZKHWKHU3')RU
+70/SURRIRUILQDOYHUVLRQQRUPD\\RXVFDQWKHSULQWHGHGLWLRQWRFUHDWHDQHOHFWURQLF
YHUVLRQ$K\SHUWH[WPXVWEHLQFOXGHGWRWKH+RPHSDJHRIWKHMRXUQDOIURPZKLFK\RXDUH
OLFHQVLQJDWKWWSZZZVFLHQFHGLUHFWFRPVFLHQFHMRXUQDO[[[[[$VSDUWRIRXUQRUPDO
SURGXFWLRQSURFHVV\RXZLOOUHFHLYHDQHPDLOQRWLFHZKHQ\RXUDUWLFOHDSSHDUVRQ(OVHYLHU·V
RQOLQHVHUYLFH6FLHQFH'LUHFWZZZVFLHQFHGLUHFWFRP7KDWHPDLOZLOOLQFOXGHWKHDUWLFOH·V
'LJLWDO2EMHFW,GHQWLILHU'2,7KLVQXPEHUSURYLGHVWKHHOHFWURQLFOLQNWRWKHSXEOLVKHG
DUWLFOHDQGVKRXOGEHLQFOXGHGLQWKHSRVWLQJRI\RXUSHUVRQDOYHUVLRQ:HDVNWKDW\RXZDLW
XQWLO\RXUHFHLYHWKLVHPDLODQGKDYHWKH'2,WRGRDQ\SRVWLQJ
3RVWLQJWRDUHSRVLWRU\$XWKRUVPD\SRVWWKHLU$$0LPPHGLDWHO\WRWKHLUHPSOR\HU·V
LQVWLWXWLRQDOUHSRVLWRU\IRULQWHUQDOXVHRQO\DQGPD\PDNHWKHLUPDQXVFULSWSXEOLFDOO\
DYDLODEOHDIWHUWKHMRXUQDOVSHFLILFHPEDUJRSHULRGKDVHQGHG
3OHDVHDOVRUHIHUWR(OVHYLHU
V$UWLFOH3RVWLQJ3ROLF\IRUIXUWKHULQIRUPDWLRQ
)RUERRNDXWKRUVWKHIROORZLQJFODXVHVDUHDSSOLFDEOHLQDGGLWLRQWRWKHDERYH$XWKRUV
DUHSHUPLWWHGWRSODFHDEULHIVXPPDU\RIWKHLUZRUNRQOLQHRQO\<RXDUHQRWDOORZHGWR
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SULQWHGHGLWLRQWRFUHDWHDQHOHFWURQLFYHUVLRQ3RVWLQJWRDUHSRVLWRU\$XWKRUVDUHSHUPLWWHG
WRSRVWDVXPPDU\RIWKHLUFKDSWHURQO\LQWKHLULQVWLWXWLRQ·VUHSRVLWRU\
7KHVLV'LVVHUWDWLRQ,I\RXUOLFHQVHLVIRUXVHLQDWKHVLVGLVVHUWDWLRQ\RXUWKHVLVPD\EH
VXEPLWWHGWR\RXULQVWLWXWLRQLQHLWKHUSULQWRUHOHFWURQLFIRUP6KRXOG\RXUWKHVLVEHSXEOLVKHG
FRPPHUFLDOO\SOHDVHUHDSSO\IRUSHUPLVVLRQ7KHVHUHTXLUHPHQWVLQFOXGHSHUPLVVLRQIRUWKH
/LEUDU\DQG$UFKLYHVRI&DQDGDWRVXSSO\VLQJOHFRSLHVRQGHPDQGRIWKHFRPSOHWHWKHVLV
DQGLQFOXGHSHUPLVVLRQIRU80,WRVXSSO\VLQJOHFRSLHVRQGHPDQGRIWKHFRPSOHWHWKHVLV
6KRXOG\RXUWKHVLVEHSXEOLVKHGFRPPHUFLDOO\SOHDVHUHDSSO\IRUSHUPLVVLRQ

(OVHYLHU2SHQ$FFHVV7HUPVDQG&RQGLWLRQV
(OVHYLHUSXEOLVKHV2SHQ$FFHVVDUWLFOHVLQERWKLWV2SHQ$FFHVVMRXUQDOVDQGYLDLWV2SHQ
$FFHVVDUWLFOHVRSWLRQLQVXEVFULSWLRQMRXUQDOV
$XWKRUVSXEOLVKLQJLQDQ2SHQ$FFHVVMRXUQDORUZKRFKRRVHWRPDNHWKHLUDUWLFOH2SHQ
$FFHVVLQDQ(OVHYLHUVXEVFULSWLRQMRXUQDOVHOHFWRQHRIWKHIROORZLQJ&UHDWLYH&RPPRQVXVHU
OLFHQVHVZKLFKGHILQHKRZDUHDGHUPD\UHXVHWKHLUZRUN&UHDWLYH&RPPRQV$WWULEXWLRQ
/LFHQVH&&%<&UHDWLYH&RPPRQV$WWULEXWLRQ²1RQ&RPPHUFLDO6KDUH$OLNH&&%<
1&6$DQG&UHDWLYH&RPPRQV$WWULEXWLRQ²1RQ&RPPHUFLDO²1R'HULYDWLYHV&&%<
1&1'
7HUPV	&RQGLWLRQVDSSOLFDEOHWRDOO(OVHYLHU2SHQ$FFHVVDUWLFOHV
$Q\UHXVHRIWKHDUWLFOHPXVWQRWUHSUHVHQWWKHDXWKRUDVHQGRUVLQJWKHDGDSWDWLRQRIWKHDUWLFOH
QRUVKRXOGWKHDUWLFOHEHPRGLILHGLQVXFKDZD\DVWRGDPDJHWKHDXWKRU·VKRQRXURU
UHSXWDWLRQ
7KHDXWKRUVPXVWEHDSSURSULDWHO\FUHGLWHG
,IDQ\SDUWRIWKHPDWHULDOWREHXVHGIRUH[DPSOHILJXUHVKDVDSSHDUHGLQRXUSXEOLFDWLRQ
ZLWKFUHGLWRUDFNQRZOHGJHPHQWWRDQRWKHUVRXUFHLWLVWKHUHVSRQVLELOLW\RIWKHXVHUWRHQVXUH
WKHLUUHXVHFRPSOLHVZLWKWKHWHUPVDQGFRQGLWLRQVGHWHUPLQHGE\WKHULJKWVKROGHU
$GGLWLRQDO7HUPV	&RQGLWLRQVDSSOLFDEOHWRHDFK&UHDWLYH&RPPRQVXVHUOLFHQVH
&&%<<RXPD\GLVWULEXWHDQGFRS\WKHDUWLFOHFUHDWHH[WUDFWVDEVWUDFWVDQGRWKHUUHYLVHG
YHUVLRQVDGDSWDWLRQVRUGHULYDWLYHZRUNVRIRUIURPDQDUWLFOHVXFKDVDWUDQVODWLRQWRLQFOXGH
LQDFROOHFWLYHZRUNVXFKDVDQDQWKRORJ\WRWH[WRUGDWDPLQHWKHDUWLFOHLQFOXGLQJIRU
FRPPHUFLDOSXUSRVHVZLWKRXWSHUPLVVLRQIURP(OVHYLHU
&&%<1&6$)RUQRQFRPPHUFLDOSXUSRVHV\RXPD\GLVWULEXWHDQGFRS\WKHDUWLFOHFUHDWH
H[WUDFWVDEVWUDFWVDQGRWKHUUHYLVHGYHUVLRQVDGDSWDWLRQVRUGHULYDWLYHZRUNVRIRUIURPDQ
DUWLFOHVXFKDVDWUDQVODWLRQWRLQFOXGHLQDFROOHFWLYHZRUNVXFKDVDQDQWKRORJ\WRWH[WDQG
GDWDPLQHWKHDUWLFOHDQGOLFHQVHQHZDGDSWDWLRQVRUFUHDWLRQVXQGHULGHQWLFDOWHUPVZLWKRXW
SHUPLVVLRQIURP(OVHYLHU
&&%<1&1')RUQRQFRPPHUFLDOSXUSRVHV\RXPD\GLVWULEXWHDQGFRS\WKHDUWLFOHDQG
LQFOXGHLWLQDFROOHFWLYHZRUNVXFKDVDQDQWKRORJ\SURYLGHG\RXGRQRWDOWHURUPRGLI\WKH
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ă3URPRWLRQDOSXUSRVHVDGYHUWLVLQJRUPDUNHWLQJ
ă&RPPHUFLDOH[SORLWDWLRQHJDSURGXFWIRUVDOHRUORDQ
ă6\VWHPDWLFGLVWULEXWLRQIRUDIHHRUIUHHRIFKDUJH
3OHDVHUHIHUWR(OVHYLHU
V2SHQ$FFHVV3ROLF\IRUIXUWKHULQIRUPDWLRQ

2WKHU&RQGLWLRQV

Y
,I\RXZRXOGOLNHWRSD\IRUWKLVOLFHQVHQRZSOHDVHUHPLWWKLVOLFHQVHDORQJZLWK\RXU
SD\PHQWPDGHSD\DEOHWR&23<5,*+7&/($5$1&(&(17(5RWKHUZLVH\RXZLOOEH
LQYRLFHGZLWKLQKRXUVRIWKHOLFHQVHGDWH3D\PHQWVKRXOGEHLQWKHIRUPRIDFKHFN
RUPRQH\RUGHUUHIHUHQFLQJ\RXUDFFRXQWQXPEHUDQGWKLVLQYRLFHQXPEHU
2QFH\RXUHFHLYH\RXULQYRLFHIRUWKLVRUGHU\RXPD\SD\\RXULQYRLFHE\FUHGLWFDUG
3OHDVHIROORZLQVWUXFWLRQVSURYLGHGDWWKDWWLPH
0DNH3D\PHQW7R
&RS\ULJKW&OHDUDQFH&HQWHU
'HSW
32%R[
%RVWRQ0$
)RUVXJJHVWLRQVRUFRPPHQWVUHJDUGLQJWKLVRUGHUFRQWDFW5LJKWV/LQN&XVWRPHU
6XSSRUWFXVWRPHUFDUH#FRS\ULJKWFRPRUWROOIUHHLQWKH86RU

*UDWLVOLFHQVHVUHIHUHQFLQJLQWKH7RWDOILHOGDUHIUHH3OHDVHUHWDLQWKLVSULQWDEOH
OLFHQVHIRU\RXUUHIHUHQFH1RSD\PHQWLVUHTXLUHG
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$XJ
7KLVLVD/LFHQVH$JUHHPHQWEHWZHHQ-DFRE3HQQHU<RXDQG-RKQ:LOH\DQG6RQV-RKQ
:LOH\DQG6RQVSURYLGHGE\&RS\ULJKW&OHDUDQFH&HQWHU&&&7KHOLFHQVHFRQVLVWVRI
\RXURUGHUGHWDLOVWKHWHUPVDQGFRQGLWLRQVSURYLGHGE\-RKQ:LOH\DQG6RQVDQGWKH
SD\PHQWWHUPVDQGFRQGLWLRQV
$OOSD\PHQWVPXVWEHPDGHLQIXOOWR&&&)RUSD\PHQWLQVWUXFWLRQVSOHDVHVHH
LQIRUPDWLRQOLVWHGDWWKHERWWRPRIWKLVIRUP
/LFHQVH1XPEHU 
/LFHQVHGDWH $XJ
/LFHQVHGFRQWHQWSXEOLVKHU -RKQ:LOH\DQG6RQV
/LFHQVHGFRQWHQWSXEOLFDWLRQ 0DJQHWLF5HVRQDQFHLQ0HGLFLQH
/LFHQVHGFRQWHQWWLWOH 6HPL/$6(5+05VSHFWURVFRS\DW7HVODLQKXPDQEUDLQ
0HWDEROLWHTXDQWLILFDWLRQLQFRUSRUDWLQJVXEMHFWVSHFLILFPDFURPROHFXOH
UHPRYDO
/LFHQVHGFRS\ULJKWOLQH :LOH\3HULRGLFDOV,QF
/LFHQVHGFRQWHQWDXWKRU -DFRE3HQQHU5REHUW%DUWKD
/LFHQVHGFRQWHQWGDWH -XO
6WDUWSDJH QD
(QGSDJH QD
7\SHRIXVH 'LVVHUWDWLRQ7KHVLV
5HTXHVWRUW\SH $XWKRURIWKLV:LOH\DUWLFOH
)RUPDW 3ULQWDQGHOHFWURQLF
3RUWLRQ )XOODUWLFOH
:LOO\RXEHWUDQVODWLQJ" 1R
7LWOHRI\RXUWKHVLV
GLVVHUWDWLRQ
0DJQHWLF5HVRQDQFH6SHFWURVFRS\,QYHVWLJDWLRQVRI$O]KHLPHU
'LVHDVH
([SHFWHGFRPSOHWLRQGDWH $XJ
([SHFWHGVL]HQXPEHURI
SDJHV

7RWDO 86'
7HUPVDQG&RQGLWLRQV
7(506$1'&21',7,216
7KLVFRS\ULJKWHGPDWHULDOLVRZQHGE\RUH[FOXVLYHO\OLFHQVHGWR-RKQ:LOH\	6RQV,QFRU
RQHRILWVJURXSFRPSDQLHVHDFKD:LOH\&RPSDQ\RUKDQGOHGRQEHKDOIRIDVRFLHW\ZLWK
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FROOHFWLYHO\:,/(<%\FOLFNLQJֺDFFHSWֺLQFRQQHFWLRQZLWKFRPSOHWLQJWKLVOLFHQVLQJ
WUDQVDFWLRQ\RXDJUHHWKDWWKHIROORZLQJWHUPVDQGFRQGLWLRQVDSSO\WRWKLVWUDQVDFWLRQDORQJ
ZLWKWKHELOOLQJDQGSD\PHQWWHUPVDQGFRQGLWLRQVHVWDEOLVKHGE\WKH&RS\ULJKW&OHDUDQFH
&HQWHU,QF&&&
V%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQVDWWKHWLPHWKDW\RXRSHQHG
\RXU5LJKWVOLQNDFFRXQWWKHVHDUHDYDLODEOHDWDQ\WLPHDWKWWSP\DFFRXQWFRS\ULJKWFRP
7HUPVDQG&RQGLWLRQV
7KHPDWHULDOV\RXKDYHUHTXHVWHGSHUPLVVLRQWRUHSURGXFHRUUHXVHWKH:LOH\
0DWHULDOVDUHSURWHFWHGE\FRS\ULJKW
<RXDUHKHUHE\JUDQWHGDSHUVRQDOQRQH[FOXVLYHQRQVXEOLFHQVDEOHRQDVWDQGDORQH
EDVLVQRQWUDQVIHUDEOHZRUOGZLGHOLPLWHGOLFHQVHWRUHSURGXFHWKH:LOH\0DWHULDOVIRU
WKHSXUSRVHVSHFLILHGLQWKHOLFHQVLQJSURFHVV7KLVOLFHQVHLVIRUDRQHWLPHXVHRQO\DQG
OLPLWHGWRDQ\PD[LPXPGLVWULEXWLRQQXPEHUVSHFLILHGLQWKHOLFHQVH7KHILUVWLQVWDQFH
RIUHSXEOLFDWLRQRUUHXVHJUDQWHGE\WKLVOLFHQFHPXVWEHFRPSOHWHGZLWKLQWZR\HDUVRI
WKHGDWHRIWKHJUDQWRIWKLVOLFHQFHDOWKRXJKFRSLHVSUHSDUHGEHIRUHWKHHQGGDWHPD\
EHGLVWULEXWHGWKHUHDIWHU7KH:LOH\0DWHULDOVVKDOOQRWEHXVHGLQDQ\RWKHUPDQQHURU
IRUDQ\RWKHUSXUSRVHEH\RQGZKDWLVJUDQWHGLQWKHOLFHQVH3HUPLVVLRQLVJUDQWHG
VXEMHFWWRDQDSSURSULDWHDFNQRZOHGJHPHQWJLYHQWRWKHDXWKRUWLWOHRIWKH
PDWHULDOERRNMRXUQDODQGWKHSXEOLVKHU<RXVKDOODOVRGXSOLFDWHWKHFRS\ULJKWQRWLFH
WKDWDSSHDUVLQWKH:LOH\SXEOLFDWLRQLQ\RXUXVHRIWKH:LOH\0DWHULDO3HUPLVVLRQLV
DOVRJUDQWHGRQWKHXQGHUVWDQGLQJWKDWQRZKHUHLQWKHWH[WLVDSUHYLRXVO\SXEOLVKHG
VRXUFHDFNQRZOHGJHGIRUDOORUSDUWRIWKLV:LOH\0DWHULDO$Q\WKLUGSDUW\FRQWHQWLV
H[SUHVVO\H[FOXGHGIURPWKLVSHUPLVVLRQ
:LWKUHVSHFWWRWKH:LOH\0DWHULDOVDOOULJKWVDUHUHVHUYHG([FHSWDVH[SUHVVO\JUDQWHG
E\WKHWHUPVRIWKHOLFHQVHQRSDUWRIWKH:LOH\0DWHULDOVPD\EHFRSLHGPRGLILHG
DGDSWHGH[FHSWIRUPLQRUUHIRUPDWWLQJUHTXLUHGE\WKHQHZ3XEOLFDWLRQWUDQVODWHG
UHSURGXFHGWUDQVIHUUHGRUGLVWULEXWHGLQDQ\IRUPRUE\DQ\PHDQVDQGQRGHULYDWLYH
ZRUNVPD\EHPDGHEDVHGRQWKH:LOH\0DWHULDOVZLWKRXWWKHSULRUSHUPLVVLRQRIWKH
UHVSHFWLYHFRS\ULJKWRZQHU<RXPD\QRWDOWHUUHPRYHRUVXSSUHVVLQDQ\PDQQHUDQ\
FRS\ULJKWWUDGHPDUNRURWKHUQRWLFHVGLVSOD\HGE\WKH:LOH\0DWHULDOV<RXPD\QRW
OLFHQVHUHQWVHOOORDQOHDVHSOHGJHRIIHUDVVHFXULW\WUDQVIHURUDVVLJQWKH:LOH\
0DWHULDOVRQDVWDQGDORQHEDVLVRUDQ\RIWKHULJKWVJUDQWHGWR\RXKHUHXQGHUWRDQ\
RWKHUSHUVRQ
7KH:LOH\0DWHULDOVDQGDOORIWKHLQWHOOHFWXDOSURSHUW\ULJKWVWKHUHLQVKDOODWDOOWLPHV
UHPDLQWKHH[FOXVLYHSURSHUW\RI-RKQ:LOH\	6RQV,QFWKH:LOH\&RPSDQLHVRUWKHLU
UHVSHFWLYHOLFHQVRUVDQG\RXULQWHUHVWWKHUHLQLVRQO\WKDWRIKDYLQJSRVVHVVLRQRIDQG
WKHULJKWWRUHSURGXFHWKH:LOH\0DWHULDOVSXUVXDQWWR6HFWLRQKHUHLQGXULQJWKH
FRQWLQXDQFHRIWKLV$JUHHPHQW<RXDJUHHWKDW\RXRZQQRULJKWWLWOHRULQWHUHVWLQRUWR
WKH:LOH\0DWHULDOVRUDQ\RIWKHLQWHOOHFWXDOSURSHUW\ULJKWVWKHUHLQ<RXVKDOOKDYHQR
ULJKWVKHUHXQGHURWKHUWKDQWKHOLFHQVHDVSURYLGHGIRUDERYHLQ6HFWLRQ1RULJKW
OLFHQVHRULQWHUHVWWRDQ\WUDGHPDUNWUDGHQDPHVHUYLFHPDUNRURWKHUEUDQGLQJ
0DUNVRI:,/(<RULWVOLFHQVRUVLVJUDQWHGKHUHXQGHUDQG\RXDJUHHWKDW\RXVKDOO
QRWDVVHUWDQ\VXFKULJKWOLFHQVHRULQWHUHVWZLWKUHVSHFWWKHUHWR
 
 167 
 5LJKWVOLQN3ULQWDEOH/LFHQVH
KWWSVVFRS\ULJKWFRP$SS'LVSDWFK6HUYOHW 
1(,7+(5:,/(<125,76/,&(162560$.(6$1<:$55$17<25
5(35(6(17$7,212)$1<.,1'72<2825$1<7+,5'3$57<
(;35(66,03/,('2567$78725<:,7+5(63(&7727+(0$7(5,$/6
257+($&&85$&<2)$1<,1)250$7,21&217$,1(',17+(
0$7(5,$/6,1&/8',1*:,7+287/,0,7$7,21$1<,03/,('
:$55$17<2)0(5&+$17$%,/,7<$&&85$&<6$7,6)$&725<
48$/,7<),71(66)25$3$57,&8/$5385326(86$%,/,7<
,17(*5$7,2125121,1)5,1*(0(17$1'$//68&+:$55$17,(6
$5(+(5(%<(;&/8'('%<:,/(<$1',76/,&(16256$1':$,9('
%<<28
:,/(<VKDOOKDYHWKHULJKWWRWHUPLQDWHWKLV$JUHHPHQWLPPHGLDWHO\XSRQEUHDFKRI
WKLV$JUHHPHQWE\\RX
<RXVKDOOLQGHPQLI\GHIHQGDQGKROGKDUPOHVV:,/(<LWV/LFHQVRUVDQGWKHLU
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6KRXOGDQ\SURYLVLRQRIWKLV$JUHHPHQWEHKHOGE\DFRXUWRIFRPSHWHQWMXULVGLFWLRQWR
EHLOOHJDOLQYDOLGRUXQHQIRUFHDEOHWKDWSURYLVLRQVKDOOEHGHHPHGDPHQGHGWRDFKLHYH
DVQHDUO\DVSRVVLEOHWKHVDPHHFRQRPLFHIIHFWDVWKHRULJLQDOSURYLVLRQDQGWKHOHJDOLW\
YDOLGLW\DQGHQIRUFHDELOLW\RIWKHUHPDLQLQJSURYLVLRQVRIWKLV$JUHHPHQWVKDOOQRWEH
DIIHFWHGRULPSDLUHGWKHUHE\
7KHIDLOXUHRIHLWKHUSDUW\WRHQIRUFHDQ\WHUPRUFRQGLWLRQRIWKLV$JUHHPHQWVKDOOQRW
FRQVWLWXWHDZDLYHURIHLWKHUSDUW\
VULJKWWRHQIRUFHHDFKDQGHYHU\WHUPDQGFRQGLWLRQ
RIWKLV$JUHHPHQW1REUHDFKXQGHUWKLVDJUHHPHQWVKDOOEHGHHPHGZDLYHGRUH[FXVHG
E\HLWKHUSDUW\XQOHVVVXFKZDLYHURUFRQVHQWLVLQZULWLQJVLJQHGE\WKHSDUW\JUDQWLQJ
VXFKZDLYHURUFRQVHQW7KHZDLYHUE\RUFRQVHQWRIDSDUW\WRDEUHDFKRIDQ\
SURYLVLRQRIWKLV$JUHHPHQWVKDOOQRWRSHUDWHRUEHFRQVWUXHGDVDZDLYHURIRUFRQVHQW
WRDQ\RWKHURUVXEVHTXHQWEUHDFKE\VXFKRWKHUSDUW\
7KLV$JUHHPHQWPD\QRWEHDVVLJQHGLQFOXGLQJE\RSHUDWLRQRIODZRURWKHUZLVHE\
\RXZLWKRXW:,/(<
VSULRUZULWWHQFRQVHQW
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DOOSULRUDJUHHPHQWVDQGUHSUHVHQWDWLRQVRIWKHSDUWLHVRUDORUZULWWHQ7KLV$JUHHPHQW
PD\QRWEHDPHQGHGH[FHSWLQZULWLQJVLJQHGE\ERWKSDUWLHV7KLV$JUHHPHQWVKDOOEH
ELQGLQJXSRQDQGLQXUHWRWKHEHQHILWRIWKHSDUWLHV
VXFFHVVRUVOHJDOUHSUHVHQWDWLYHV
DQGDXWKRUL]HGDVVLJQV
,QWKHHYHQWRIDQ\FRQIOLFWEHWZHHQ\RXUREOLJDWLRQVHVWDEOLVKHGE\WKHVHWHUPVDQG
FRQGLWLRQVDQGWKRVHHVWDEOLVKHGE\&&&ֺV%LOOLQJDQG3D\PHQWWHUPVDQGFRQGLWLRQV
WKHVHWHUPVDQGFRQGLWLRQVVKDOOSUHYDLO
:,/(<H[SUHVVO\UHVHUYHVDOOULJKWVQRWVSHFLILFDOO\JUDQWHGLQWKHFRPELQDWLRQRIL
WKHOLFHQVHGHWDLOVSURYLGHGE\\RXDQGDFFHSWHGLQWKHFRXUVHRIWKLVOLFHQVLQJ
WUDQVDFWLRQLLWKHVHWHUPVDQGFRQGLWLRQVDQGLLL&&&ֺV%LOOLQJDQG3D\PHQWWHUPV
DQGFRQGLWLRQV
7KLV$JUHHPHQWZLOOEHYRLGLIWKH7\SHRI8VH)RUPDW&LUFXODWLRQRU5HTXHVWRU
7\SHZDVPLVUHSUHVHQWHGGXULQJWKHOLFHQVLQJSURFHVV
7KLV$JUHHPHQWVKDOOEHJRYHUQHGE\DQGFRQVWUXHGLQDFFRUGDQFHZLWKWKHODZVRIWKH
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YHQXHLQVXFKFRXUWDQGFRQVHQWVWRVHUYLFHRISURFHVVE\UHJLVWHUHGRUFHUWLILHGPDLO
UHWXUQUHFHLSWUHTXHVWHGDWWKHODVWNQRZQDGGUHVVRIVXFKSDUW\
:,/(<23(1$&&(667(506$1'&21',7,216
:LOH\3XEOLVKHV2SHQ$FFHVV$UWLFOHVLQIXOO\2SHQ$FFHVV-RXUQDOVDQGLQ6XEVFULSWLRQ
MRXUQDOVRIIHULQJ2QOLQH2SHQ$OWKRXJKPRVWRIWKHIXOO\2SHQ$FFHVVMRXUQDOVSXEOLVKRSHQ
DFFHVVDUWLFOHVXQGHUWKHWHUPVRIWKH&UHDWLYH&RPPRQV$WWULEXWLRQ&&%</LFHQVHRQO\
WKHVXEVFULSWLRQMRXUQDOVDQGDIHZRIWKH2SHQ$FFHVV-RXUQDOVRIIHUDFKRLFHRI&UHDWLYH
&RPPRQV/LFHQVHV&UHDWLYH&RPPRQV$WWULEXWLRQ&&%<OLFHQVH&UHDWLYH&RPPRQV
$WWULEXWLRQ1RQ&RPPHUFLDO&&%<1&OLFHQVHDQG&UHDWLYH&RPPRQV$WWULEXWLRQ1RQ
&RPPHUFLDO1R'HULYV&&%<1&1'/LFHQVH7KHOLFHQVHW\SHLVFOHDUO\LGHQWLILHGRQWKH
DUWLFOH
&RS\ULJKWLQDQ\UHVHDUFKDUWLFOHLQDMRXUQDOSXEOLVKHGDV2SHQ$FFHVVXQGHUD&UHDWLYH
&RPPRQV/LFHQVHLVUHWDLQHGE\WKHDXWKRUV$XWKRUVJUDQW:LOH\DOLFHQVHWRSXEOLVKWKH
DUWLFOHDQGLGHQWLI\LWVHOIDVWKHRULJLQDOSXEOLVKHU$XWKRUVDOVRJUDQWDQ\WKLUGSDUW\WKHULJKW
WRXVHWKHDUWLFOHIUHHO\DVORQJDVLWVLQWHJULW\LVPDLQWDLQHGDQGLWVRULJLQDODXWKRUVFLWDWLRQ
GHWDLOVDQGSXEOLVKHUDUHLGHQWLILHGDVIROORZV>7LWOHRI$UWLFOH$XWKRU-RXUQDO7LWOHDQG
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